PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19782978-0	2010	Insulin-like growth factor-1 and insulin-like growth factor-binding protein-1 in patients with polycystic ovary syndrome during clomiphene citrate therapy.	Clomiphene	128-146	insulin like growth factor 1	Homo sapiens	0-77
20981331-2	2011	The present study aimed to evaluate whether the following endometrial receptivity factors: the endometrial morphology, the hormone concentrations, and the protein expression of endometrial leukaemia-inhibitory factor (LIF) and osteopontin (OPN) could be improved by the acupuncture in clomiphene citrate(CC)-induced rat model during implantation period.	Clomiphene	285-303	LIF, interleukin 6 family cytokine	Rattus norvegicus	189-216
19143734-3	2009	Our patient with vascular hypogonadism was treated with testosterone and clomiphene citrate in cycles; with a hope of improving not only androgen levels but overall pituitary function as there were co-existing endocrine pathologies of albeit primary hypothyroidism and low IGF-1 levels.	Clomiphene	73-91	insulin like growth factor 1	Homo sapiens	273-278
19401323-0	2009	Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome.	Clomiphene	0-18	follicle stimulating hormone receptor	Homo sapiens	45-82
19371211-4	2009	Because congenital thrombophilia is a moderate risk factor for central retinal vein occlusion and the administration of clomiphene may trigger this process, we recommend screening of young patients for FV Leiden before clomiphene treatment.	Clomiphene	120-130	coagulation factor V	Homo sapiens	202-211
19640893-6	2009	RESULTS: The pretreatment median (range) plasma AMH concentrations were 6.1 (1.0-21.0) and 5.7 (1.3-9.5) ng/ml in women having LOD and clomiphene citrate treatment, respectively.	Clomiphene	135-153	anti-Mullerian hormone	Homo sapiens	48-51
19640893-10	2009	For all patients (n = 47, clomiphene citrate or LOD), plasma AMH >or=7.7 ng/ml was associated with a reduced chance of ovulation after treatment (P = 0.004).	Clomiphene	26-44	anti-Mullerian hormone	Homo sapiens	61-64
19634921-7	2009	Therefore, current data support the use of insulin sensitizers, along with lifestyle measures and/or other agents, in women with PCOS, especially in the presence of insulin- or clomifene-resistance.	Clomiphene	177-186	insulin	Homo sapiens	43-50
19211805-0	2009	Clomiphene citrate causes aberrant tubal apoptosis and estrogen receptor activation in rat fallopian tube: implications for tubal ectopic pregnancy.	Clomiphene	0-18	estrogen receptor 1	Rattus norvegicus	55-72
19522426-13	2009	CONCLUSION: The ovulatory response to clomifene can be increased in polycystic ovary syndrome women by decreasing insulin secretion with metformin.	Clomiphene	38-47	insulin	Homo sapiens	114-121
18249394-0	2009	Effects of letrozole and clomiphene citrate on the expression of HOXA10 and integrin alpha v beta 3 in uterine epithelium of rats.	Clomiphene	25-43	homeobox A10	Rattus norvegicus	65-71
18249394-1	2009	OBJECTIVE: To compare the effects of letrozole and clomiphene citrate on the expression of HOXA10 and integrin alpha(v)beta(3) in the uterine epithelium in rats.	Clomiphene	51-69	homeobox A10	Rattus norvegicus	91-97
18445989-0	2008	CYP2D6 is primarily responsible for the metabolism of clomiphene.	Clomiphene	54-64	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
19552097-3	2008	The hypothesis is that by improving insulin- resistance and thus reversing from hyperinsulinaemia towards normal insulin secretion will enhance the responsiveness of these women to ovulation inducing effects of clomiphene.	Clomiphene	211-221	insulin	Homo sapiens	36-43
19552097-3	2008	The hypothesis is that by improving insulin- resistance and thus reversing from hyperinsulinaemia towards normal insulin secretion will enhance the responsiveness of these women to ovulation inducing effects of clomiphene.	Clomiphene	211-221	insulin	Homo sapiens	85-92
18279543-4	2008	We discuss the estrogenic and anti-estrogenic effects of early SERMs, such as clomiphene citrate, used for treatment of ovulation induction, and the triphenylethylene, tamoxifen, which has ER antagonist activity in the breast, and is used for prevention and treatment of ER-positive breast cancer.	Clomiphene	78-96	estrogen receptor 1	Homo sapiens	64-66
18445989-5	2008	The aim of the present work was to define the role of CYP2D6 and CYP3A4 in the in vitro metabolism of enclomiphene, regarded by some as the more active isomer of clomiphene.	Clomiphene	104-114	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	54-60
18445989-5	2008	The aim of the present work was to define the role of CYP2D6 and CYP3A4 in the in vitro metabolism of enclomiphene, regarded by some as the more active isomer of clomiphene.	Clomiphene	104-114	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-71
18510043-6	2008	Clomiphene does not have influence on elementary factor in PCOS which seems to be opportunity to insulin.	Clomiphene	0-10	insulin	Homo sapiens	97-104
16984518-0	2006	Role of aromatase inhibitor in ovulation induction in patients with poor response to clomiphene citrate.	Clomiphene	85-103	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	8-17
18028738-6	2007	There was a significant difference in AMH concentration between women with PCOS and the control group (P < 0.05) and also between women with PCOS who responded to clomiphene citrate and those who did not (P < 0.01).	Clomiphene	166-184	anti-Mullerian hormone	Homo sapiens	38-41
18028738-7	2007	A value of 1.2 ng/ml AMH could be used to predict response to clomiphene citrate in obese women with PCOS (sensitivity 71%, specificity 65.7%).	Clomiphene	62-80	anti-Mullerian hormone	Homo sapiens	21-24
18028738-9	2007	AMH measurement could also be useful in the prediction of ovarian response to clomiphene citrate.	Clomiphene	78-96	anti-Mullerian hormone	Homo sapiens	0-3
16841076-4	2007	Ovariectomy or pretreatment with either finasteride (a 5alpha-reductase inhibitor) or clomiphene (an estrogen receptor antagonist) prevented this ethanol-induced increase in dopamine concentration.	Clomiphene	86-96	estrogen receptor 1	Rattus norvegicus	101-118
17054466-12	2006	CONCLUSIONS: Our study demonstrates for the first time that raloxifene and clomiphene affect the secretion of PRL in postmenopausal women in a similar manner.	Clomiphene	75-85	prolactin	Homo sapiens	110-113
17845343-0	2007	Role of aromatase inhibitor in patients with poor response to clomiphene citrate needs further evaluation.	Clomiphene	62-80	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	8-17
16291975-2	2005	Clomiphene increases endogenous gonadotropin-releasing hormone secretion from the hypothalamus and gonadotropin hormone secretion directly from the pituitary and, thus, increases intratesticular testosterone concentration.	Clomiphene	0-10	gonadotropin releasing hormone 1	Homo sapiens	32-62
16478764-7	2006	RESULTS: Mean total E2 and E2 per mature follicle were significantly higher in clomiphene group without a difference in mean number of mature follicles >18 mm and ovulation rate.	Clomiphene	79-89	cystatin 12, pseudogene	Homo sapiens	20-29
15511333-0	2004	Evaluation of a pen device for self-administration of recombinant human FSH in clomiphene citrate-resistant anovulatory women undergoing ovulation induction.	Clomiphene	79-97	proprotein convertase subtilisin/kexin type 1 inhibitor	Homo sapiens	16-19
15586646-2	2004	The goal of this study was to elucidate whether hCG administration at 24 or 36 hours after clomiphene citrate stimulation impacts pregnancy rates.	Clomiphene	91-109	hypertrichosis 2 (generalised, congenital)	Homo sapiens	48-51
15498183-1	2004	OBJECTIVE: To investigate the effects of metformin and clomiphene on infertility caused by polycystic ovary syndrome (PCOS) with insulin-resistance (IR) and to observe the effects of metformin on PCOS with pseudoacanthosis nigricans (AN) and IR.	Clomiphene	55-65	insulin	Homo sapiens	129-136
14648180-4	2004	PATIENTS: One hundred polycystic ovary patients and normal prolactin (PRL) who were clomiphene citrate resistant.	Clomiphene	84-102	prolactin	Homo sapiens	59-68
15120636-0	2004	Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation.	Clomiphene	88-98	potassium voltage-gated channel subfamily H member 2	Homo sapiens	46-50
15120636-3	2004	We describe here a potent inhibitory effect (IC(50) = 0.18 microM) of clomiphene on HERG ionic current (I(HERG)) recorded from a mammalian cell line expressing HERG channels.	Clomiphene	70-80	potassium voltage-gated channel subfamily H member 2	Homo sapiens	84-88
15120636-3	2004	We describe here a potent inhibitory effect (IC(50) = 0.18 microM) of clomiphene on HERG ionic current (I(HERG)) recorded from a mammalian cell line expressing HERG channels.	Clomiphene	70-80	potassium voltage-gated channel subfamily H member 2	Homo sapiens	106-110
15120636-3	2004	We describe here a potent inhibitory effect (IC(50) = 0.18 microM) of clomiphene on HERG ionic current (I(HERG)) recorded from a mammalian cell line expressing HERG channels.	Clomiphene	70-80	potassium voltage-gated channel subfamily H member 2	Homo sapiens	106-110
15120636-4	2004	Inhibition of I(HERG) by clomiphene showed voltage-dependence and developed quickly following membrane depolarisation, indicating contingency of block on HERG channel gating.	Clomiphene	25-35	potassium voltage-gated channel subfamily H member 2	Homo sapiens	16-20
15120636-4	2004	Inhibition of I(HERG) by clomiphene showed voltage-dependence and developed quickly following membrane depolarisation, indicating contingency of block on HERG channel gating.	Clomiphene	25-35	potassium voltage-gated channel subfamily H member 2	Homo sapiens	154-158
15120636-5	2004	At 100 nM, clomiphene and the related anti-estrogen tamoxifen produced similar levels of I(HERG) blockade (p > 0.05).	Clomiphene	11-21	potassium voltage-gated channel subfamily H member 2	Homo sapiens	91-95
15120636-7	2004	The disparity between clomiphene"s potent I(HERG) inhibition and its lack of effect on the QT interval underscores the notion that I(HERG) pharmacology may best be used alongside other screening methods when investigating the QT-prolonging tendency and related cardiotoxicity of non-cardiac drugs.	Clomiphene	22-32	potassium voltage-gated channel subfamily H member 2	Homo sapiens	44-48
15120636-7	2004	The disparity between clomiphene"s potent I(HERG) inhibition and its lack of effect on the QT interval underscores the notion that I(HERG) pharmacology may best be used alongside other screening methods when investigating the QT-prolonging tendency and related cardiotoxicity of non-cardiac drugs.	Clomiphene	22-32	potassium voltage-gated channel subfamily H member 2	Homo sapiens	133-137
14648180-12	2004	CONCLUSIONS: The only significant effect of long-term bromocriptin therapy in clomiphene citrate resistant polycystic ovary women was to lower the serum prolactin concentration.	Clomiphene	78-96	prolactin	Homo sapiens	153-162
12831586-1	2003	Clomiphene citrate treatment with the association of gonadotrophins and the GnRH antagonist cetrorelix 0.25mg was analysed in two different stimulation protocols for IVF.	Clomiphene	0-18	gonadotropin releasing hormone 1	Homo sapiens	76-80
12790840-13	2003	Low IL-6 levels in chronic anovulation may be a marker of resistance to clomiphene citrate.	Clomiphene	72-90	interleukin 6	Homo sapiens	4-8
12725382-8	2003	The determined hormonal activities of estrogens on the interaction of YFP-hERalpha with ERE were as follows in their decreasing order: diethylstilbestrol (DES) > 17beta-estradiol (E2) <==> ethynylestradiol (EE2) > 4-hydroxy tamoxifen (OHT) > clomiphene (Clo).	Clomiphene	269-272	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	74-82
14676484-5	2003	The recent introduction of the insulin-sensitizing agents as adjuvants to clomiphene citrate and gonadotropins has changed the treatment strategy.	Clomiphene	74-92	insulin	Homo sapiens	31-38
12725382-8	2003	The determined hormonal activities of estrogens on the interaction of YFP-hERalpha with ERE were as follows in their decreasing order: diethylstilbestrol (DES) > 17beta-estradiol (E2) <==> ethynylestradiol (EE2) > 4-hydroxy tamoxifen (OHT) > clomiphene (Clo).	Clomiphene	257-267	Era like 12S mitochondrial rRNA chaperone 1	Homo sapiens	74-82
12571165-1	2003	BACKGROUND: Recognition of the importance of insulin resistance in clomiphene-resistant women with polycystic ovary syndrome (PCOS) has led to the use of insulin sensitizers.	Clomiphene	67-77	insulin	Homo sapiens	45-52
12571165-1	2003	BACKGROUND: Recognition of the importance of insulin resistance in clomiphene-resistant women with polycystic ovary syndrome (PCOS) has led to the use of insulin sensitizers.	Clomiphene	67-77	insulin	Homo sapiens	154-161
12593999-0	2003	Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.	Clomiphene	113-131	insulin	Homo sapiens	14-21
12593999-1	2003	OBJECTIVE: To investigate the effects of combined rosiglitazone and clomiphene citrate versus clomiphene citrate monotherapy on serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels in polycystic ovary syndrome (PCOS) and to evaluate these therapeutic interventions in the link between hyperinsulinemia and hormonal perturbations in PCOS.	Clomiphene	68-86	insulin like growth factor 1	Homo sapiens	134-162
12593999-8	2003	RESULTS: Combined rosiglitazone and clomiphene treatment led to a significant reduction in area under the insulin curve (AUC insulin), whereas clomiphene monotherapy did not lead to this reduction.	Clomiphene	36-46	insulin	Homo sapiens	106-113
12593999-8	2003	RESULTS: Combined rosiglitazone and clomiphene treatment led to a significant reduction in area under the insulin curve (AUC insulin), whereas clomiphene monotherapy did not lead to this reduction.	Clomiphene	36-46	insulin	Homo sapiens	125-132
12593999-12	2003	CONCLUSION: Combined rosiglitazone and clomiphene was an effective therapeutic regimen for correcting insulin resistance in patients with PCOS, possibly by reducing IGF1 bioavailability to the ovaries, thus modifying the hyperandrogenic intrafollicular milieu that occurs in PCOS.	Clomiphene	39-49	insulin	Homo sapiens	102-109
12593999-12	2003	CONCLUSION: Combined rosiglitazone and clomiphene was an effective therapeutic regimen for correcting insulin resistance in patients with PCOS, possibly by reducing IGF1 bioavailability to the ovaries, thus modifying the hyperandrogenic intrafollicular milieu that occurs in PCOS.	Clomiphene	39-49	insulin like growth factor 1	Homo sapiens	165-169
12008099-1	2002	The effect of clomiphene, an ovulation-inducing agent, on cytosolic free Ca(2+) levels ([Ca(2+)](i)) in populations of PC3 human prostate cancer cells was explored by using fura-2 as a Ca(2+) indicator.	Clomiphene	14-24	chromobox 8	Homo sapiens	119-122
29662350-11	2002	The clomiphene treatment increased serum E2 but decreased PRL concentrations.	Clomiphene	4-14	prolactin	Homo sapiens	58-61
12390089-9	2002	Multivariate analysis showed that the basal serum testosterone level was the only variable in predicting the probability of response to the clomiphene in terms of true-corrected seminal fructose, seminal acid phosphatase and seminal alpha-glucosidase levels.	Clomiphene	140-150	sucrase-isomaltase	Homo sapiens	233-250
12218667-7	2002	The introduction of the insulin-sensitizing agents as adjuvants to clomiphene citrate and gonadotropins has changed the treatment strategy.	Clomiphene	67-85	insulin	Homo sapiens	24-31
12004198-3	2002	The estrogen receptor ligands tamoxifen, nafoxidine and clomiphene were identified as agents which affect mitochondrial membrane potential in a cyclosporin A-like manner.	Clomiphene	56-66	estrogen receptor 1	Homo sapiens	4-21
12008099-10	2002	Collectively, the results suggest that clomiphene induced [Ca(2+)](i) increases in PC3 cells by releasing store Ca(2+) from multiple stores in an phospholipase C-independent manner, and by activating Ca(2+) influx; and clomiphene was of mild cytotoxicity.	Clomiphene	39-49	chromobox 8	Homo sapiens	83-86
12008099-10	2002	Collectively, the results suggest that clomiphene induced [Ca(2+)](i) increases in PC3 cells by releasing store Ca(2+) from multiple stores in an phospholipase C-independent manner, and by activating Ca(2+) influx; and clomiphene was of mild cytotoxicity.	Clomiphene	219-229	chromobox 8	Homo sapiens	83-86
11937125-1	2002	OBJECTIVE: To investigate the effect that clomiphene citrate exerts on luteinizing hormone (LH) concentrations in gonadotropin/gonadotropin-releasing hormone (GnRH) antagonist cycles.	Clomiphene	42-60	gonadotropin releasing hormone 1	Homo sapiens	114-157
11937125-1	2002	OBJECTIVE: To investigate the effect that clomiphene citrate exerts on luteinizing hormone (LH) concentrations in gonadotropin/gonadotropin-releasing hormone (GnRH) antagonist cycles.	Clomiphene	42-60	gonadotropin releasing hormone 1	Homo sapiens	159-163
11591271-8	2001	Obesity, hyperandrogenaemia and insulin resistance are important factors in clomiphene-resistant patients.	Clomiphene	76-86	insulin	Homo sapiens	32-39
12012626-1	2002	The aim of this study was to compare endometrial leukemia inhibitory factor (LIF) levels in spontaneous and clomiphene citrate (CC)-induced cycles of patients with unexplained infertility.	Clomiphene	108-126	LIF interleukin 6 family cytokine	Homo sapiens	49-75
12012626-1	2002	The aim of this study was to compare endometrial leukemia inhibitory factor (LIF) levels in spontaneous and clomiphene citrate (CC)-induced cycles of patients with unexplained infertility.	Clomiphene	108-126	LIF interleukin 6 family cytokine	Homo sapiens	77-80
11893011-0	2002	Vascular endothelial growth factor concentrations in follicular fluid obtained from IVF-ET patients: a comparison of hMG, clomiphene citrate, and natural cycle.	Clomiphene	122-140	vascular endothelial growth factor A	Homo sapiens	0-34
11679509-2	2001	A prospective, controlled study was carried out to investigate the effect of clomiphene citrate (CC) on secretions of beta1, alpha3 and alphaV integrin molecules in the endometrium of patients with unexplained infertility during the implantation window.	Clomiphene	77-95	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	118-123
11597618-0	2001	Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.	Clomiphene	22-32	insulin	Homo sapiens	0-7
11821072-6	2002	RESULT(S): Studies have demonstrated that insulin-sensitizing drugs can increase spontaneous ovulation, enhance the induction of ovulation with clomiphene citrate, and increase clinical pregnancy rates.	Clomiphene	144-162	insulin	Homo sapiens	42-49
11451549-4	2001	Fifteen patients of GnRH antagonist group were treated with the combination of GnRH antagonist with clomiphene citrate (CC) plus gonadotropins, while six patients were treated with the combination of GnRH antagonist plus gonadotropins, but without CC.	Clomiphene	100-118	gonadotropin releasing hormone 1	Homo sapiens	20-24
11408780-7	2001	Furthermore, injection of an estrogen receptor blocker, clomiphene, together with testosterone, abolished the testosterone-induced increase in Fos-positive nuclei, thus confirming the finding that testosterone induces c-fos by acting through estrogen receptors.	Clomiphene	56-66	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	143-146
11408780-7	2001	Furthermore, injection of an estrogen receptor blocker, clomiphene, together with testosterone, abolished the testosterone-induced increase in Fos-positive nuclei, thus confirming the finding that testosterone induces c-fos by acting through estrogen receptors.	Clomiphene	56-66	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	218-223
11056123-0	2000	Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome.	Clomiphene	0-18	insulin	Homo sapiens	29-36
11120504-5	2000	In women with anovulatory infertility caused by hyperandrogenism and insulin resistance, clomiphene citrate treatment often fails to result in pregnancy.	Clomiphene	89-107	insulin	Homo sapiens	69-76
11120504-6	2000	For these women, weight loss and insulin sensitizers can be effective methods of inducing ovulation and pregnancy and may reduce the number of clomiphene-resistant women with polycystic ovary syndrome who are treated with gonadotropins, ovarian surgery, or in vitro fertilization-embryo transfer.	Clomiphene	143-153	insulin	Homo sapiens	33-40
11056123-0	2000	Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome.	Clomiphene	0-18	insulin like growth factor 1	Homo sapiens	86-114
11056123-0	2000	Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome.	Clomiphene	0-18	insulin	Homo sapiens	86-93
11056123-2	2000	It was demonstrated that administration of clomiphene to women with polycystic ovarian syndrome (PCOS) is accompanied by a reduction in plasma concentrations of insulin-like growth factor-I (IGF-I).	Clomiphene	43-53	insulin like growth factor 1	Homo sapiens	161-189
11056123-2	2000	It was demonstrated that administration of clomiphene to women with polycystic ovarian syndrome (PCOS) is accompanied by a reduction in plasma concentrations of insulin-like growth factor-I (IGF-I).	Clomiphene	43-53	insulin like growth factor 1	Homo sapiens	191-196
11056123-4	2000	The aim of the present study was to evaluate the effect of clomiphene on plasma concentrations of IGF-I and IGF binding protein (IGFBP)-1 and on insulin resistance associated with PCOS.	Clomiphene	59-69	insulin like growth factor 1	Homo sapiens	98-103
11056123-4	2000	The aim of the present study was to evaluate the effect of clomiphene on plasma concentrations of IGF-I and IGF binding protein (IGFBP)-1 and on insulin resistance associated with PCOS.	Clomiphene	59-69	insulin like growth factor binding protein 1	Homo sapiens	108-137
11056123-10	2000	Plasma concentrations of IGF-I decreased by 31.5% (434 +/- 84 versus 297 +/- 71 ng/ml; P: < 0.05) after 5 days of clomiphene therapy, whereas plasma concentrations of IGFBP-1 increased by approximately 28.1% (26.3 +/- 4 versus 36.6 +/- 7 ng/ml; P: < 0.05).	Clomiphene	117-127	insulin like growth factor 1	Homo sapiens	25-30
11056123-13	2000	The present results show that clomiphene does not cause changes in insulin resistance associated with PCOS but reduces plasma concentrations of IGF-I and increases those of IGFBP-1, with a consequent marked reduction in the IGF-I:IGFBP-1 ratio.	Clomiphene	30-40	insulin like growth factor 1	Homo sapiens	144-149
11056123-13	2000	The present results show that clomiphene does not cause changes in insulin resistance associated with PCOS but reduces plasma concentrations of IGF-I and increases those of IGFBP-1, with a consequent marked reduction in the IGF-I:IGFBP-1 ratio.	Clomiphene	30-40	insulin like growth factor binding protein 1	Homo sapiens	173-180
11056123-13	2000	The present results show that clomiphene does not cause changes in insulin resistance associated with PCOS but reduces plasma concentrations of IGF-I and increases those of IGFBP-1, with a consequent marked reduction in the IGF-I:IGFBP-1 ratio.	Clomiphene	30-40	insulin like growth factor 1	Homo sapiens	224-229
11056123-13	2000	The present results show that clomiphene does not cause changes in insulin resistance associated with PCOS but reduces plasma concentrations of IGF-I and increases those of IGFBP-1, with a consequent marked reduction in the IGF-I:IGFBP-1 ratio.	Clomiphene	30-40	insulin like growth factor binding protein 1	Homo sapiens	230-237
11075292-0	2000	Cyclic changes in serum levels of insulin-like growth factor binding protein-1 in women treated with clomiphene citrate and tamoxifen.	Clomiphene	101-119	insulin like growth factor binding protein 1	Homo sapiens	34-78
11075292-6	2000	In clomiphene citrate and control groups, a significant positive correlation was found between circulating IGFBP-1 and estradiol, and between serum levels of IGFBP-1 and inhibin A at the preovulatory stage (on day 13).	Clomiphene	3-21	insulin like growth factor binding protein 1	Homo sapiens	107-114
11075292-6	2000	In clomiphene citrate and control groups, a significant positive correlation was found between circulating IGFBP-1 and estradiol, and between serum levels of IGFBP-1 and inhibin A at the preovulatory stage (on day 13).	Clomiphene	3-21	insulin like growth factor binding protein 1	Homo sapiens	158-165
11075292-9	2000	In conclusion, the preovulatory peak of circulating IGFBP-1 can be induced in cycles treated with both clomiphene citrate and tamoxifen.	Clomiphene	103-121	insulin like growth factor binding protein 1	Homo sapiens	52-59
11075292-10	2000	In addition, a significant positive correlation between estradiol, inhibin A and IGFBP-1 at the preovulatory stage indicates that IGFBP-1 may also reflect follicular development and may further be used as an additional indicator to monitor folliculogenesis under clomiphene citrate treatment.	Clomiphene	263-281	insulin like growth factor binding protein 1	Homo sapiens	81-88
11075292-10	2000	In addition, a significant positive correlation between estradiol, inhibin A and IGFBP-1 at the preovulatory stage indicates that IGFBP-1 may also reflect follicular development and may further be used as an additional indicator to monitor folliculogenesis under clomiphene citrate treatment.	Clomiphene	263-281	insulin like growth factor binding protein 1	Homo sapiens	130-137
10627770-1	1998	Luteinizing hormone releasing hormone (LHRH) agonists have been used in conjunction with gonadotrophins, and occasionally with pulsatile LHRH, for ovulation induction in women with clomiphene-citrate-resistant polycystic ovary syndrome (PCOS) and also for superovulation for in vitro fertilization (IVF) and gamete intrafallopian transfer in women with PCOS.	Clomiphene	181-191	gonadotropin releasing hormone 1	Homo sapiens	0-37
11421528-8	2000	Endogenous testosterone elevation from clomiphene stimulation raised PSA levels the highest, and testosterone patches yielded the least PSA response.	Clomiphene	39-49	kallikrein related peptidase 3	Homo sapiens	69-72
10796718-5	2000	OBJECTIVES: To assess the effectiveness of pulsatile GnRH administration in women with clomiphene-resistant polycystic ovary syndrome (PCOS), in terms of ovulation induction, pregnancy, miscarriage, multiple pregnancy and ovarian hyperstimulation syndrome (OHSS).	Clomiphene	87-97	gonadotropin releasing hormone 1	Homo sapiens	53-57
9987735-1	1999	Insulin resistance and ovulatory responses to clomiphene citrate.	Clomiphene	46-64	insulin	Homo sapiens	0-7
9987735-2	1999	OBJECTIVE: To evaluate insulin secretion detected on oral glucose tolerance testing in relation to clomiphene citrate (CC) responses in women with polycystic ovary syndrome (PCOS).	Clomiphene	99-117	insulin	Homo sapiens	23-30
10411795-0	1999	Localization and expression of oxytocin receptor and its messenger ribonucleic acid in peri-implantation phase human endometrium during control and clomiphene-treated cycles.	Clomiphene	148-158	oxytocin/neurophysin I prepropeptide	Homo sapiens	31-39
10411795-1	1999	OBJECTIVES: This study was undertaken to determine expression levels of oxytocin receptor and its gene in peri-implantation phase human endometrium during clomiphene-treated cycles compared with control cycles.	Clomiphene	155-165	oxytocin/neurophysin I prepropeptide	Homo sapiens	72-80
10411795-2	1999	STUDY DESIGN: Oxytocin receptor and its messenger ribonucleic acid in peri-implantation phase endometrium during control and clomiphene-treated (50 mg days 5 to 9) cycles of 5 healthy fertile women were determined by immunohistochemical methods, Western blot analysis with monoclonal antibody against amino acids 20 through 40 of the extracellular N-terminal human oxytocin receptor, and reverse transcription-polymerase chain reaction with oligonucleotide primers to amplify the 391-base pair fragment of the oxytocin receptor gene.	Clomiphene	125-135	oxytocin/neurophysin I prepropeptide	Homo sapiens	14-22
10411795-3	1999	RESULTS: Oxytocin receptor and its messenger ribonucleic acid were expressed in human peri-implantation phase endometrial samples from both control and clomiphene-treated cycles.	Clomiphene	152-162	oxytocin/neurophysin I prepropeptide	Homo sapiens	9-17
10411795-5	1999	Oxytocin receptor protein was separated out as a single 70-kd band by Western blot analysis; its relative abundance was significantly reduced during clomiphene-treated cycles.	Clomiphene	149-159	oxytocin receptor	Homo sapiens	0-17
10627770-1	1998	Luteinizing hormone releasing hormone (LHRH) agonists have been used in conjunction with gonadotrophins, and occasionally with pulsatile LHRH, for ovulation induction in women with clomiphene-citrate-resistant polycystic ovary syndrome (PCOS) and also for superovulation for in vitro fertilization (IVF) and gamete intrafallopian transfer in women with PCOS.	Clomiphene	181-191	gonadotropin releasing hormone 1	Homo sapiens	39-43
9691973-12	1998	Both clomiphene citrate and onapristone suppressed connexin-43 expression, and concomitant addition of hCG did not counteract their effect.	Clomiphene	5-23	gap junction protein alpha 1	Homo sapiens	51-62
9823719-1	1998	High-performance affinity chromatography and zonal elution studies were used to examine the binding that takes place between the drug clomiphene and the protein human serum albumin (HSA).	Clomiphene	134-144	albumin	Homo sapiens	167-180
9714066-6	1998	Structure-activity relationship studies demonstrated chemical requirements for PKC-epsilon translocation, with tamoxifen, 3-OH-tamoxifen and clomiphene being active.	Clomiphene	141-151	protein kinase C epsilon	Homo sapiens	79-90
9730919-6	1998	These compounds, as well as the fungicide tridemorph and the clinically used drugs tamoxifen, clomiphene, amiodarone, and opipramol, inhibit the in vitro activity of the recombinant human EBP (IC50 = 0.015-54 microM).	Clomiphene	94-104	EBP cholestenol delta-isomerase	Homo sapiens	188-191
9637806-2	1998	We hypothesized that reducing insulin secretion by administering metformin would increase the ovulatory response to clomiphene.	Clomiphene	116-126	insulin	Homo sapiens	30-37
9637806-7	1998	Among the 21 women given metformin plus clomiphene, the mean (+/-SE) area under the serum insulin curve after oral glucose administration decreased from 6745+/-2021 to 3479+/-455 microU per milliliter per minute (40.5+/-12.1 to 20.9+/-2.7 nmol per liter per minute, P=0.03), but it did not change significantly in the 25 women given placebo plus clomiphene.	Clomiphene	40-50	insulin	Homo sapiens	90-97
9637806-7	1998	Among the 21 women given metformin plus clomiphene, the mean (+/-SE) area under the serum insulin curve after oral glucose administration decreased from 6745+/-2021 to 3479+/-455 microU per milliliter per minute (40.5+/-12.1 to 20.9+/-2.7 nmol per liter per minute, P=0.03), but it did not change significantly in the 25 women given placebo plus clomiphene.	Clomiphene	346-356	insulin	Homo sapiens	90-97
9637806-11	1998	CONCLUSIONS: The ovulatory response to clomiphene can be increased in obese women with the polycystic ovary syndrome by decreasing insulin secretion with metformin.	Clomiphene	39-49	insulin	Homo sapiens	131-138
8702220-5	1996	Tamoxifen, clomiphene, nafoxidine and ICI 182,780 significantly inhibited endothelial cell growth stimulated by bFGF and VEGF.	Clomiphene	11-21	fibroblast growth factor 2	Homo sapiens	112-116
9327780-7	1997	Treatment with antiestrogen (tamoxifen or clomiphene) abolished the LDL receptor stimulatory effect of ethynylestradiol at both the protein and mRNA levels.	Clomiphene	42-52	low density lipoprotein receptor	Rattus norvegicus	68-80
9207217-6	1997	Using a strain missing the ABC-cassette transporter Snq2, clomiphene had anti-estrogenic activity.	Clomiphene	58-68	ATP-binding cassette transporter SNQ2	Saccharomyces cerevisiae S288C	52-56
8990830-1	1996	OBJECTIVE: To determine whether the presence of insulin resistance in obese subjects would adversely affect the rate of ovulation induction by clomiphene citrate.	Clomiphene	143-161	insulin	Homo sapiens	48-55
8990830-4	1996	CONCLUSIONS: The existence of the presence of endocrine abnormalities associated with hyperinsulinemia and insulin resistance may serve as clinical indicators to help predict which obese patients are likely to respond to clomiphene citrate therapy.	Clomiphene	221-239	insulin	Homo sapiens	91-98
8997862-4	1996	It is concluded that a cyclic variation was observed in ER and PR binding sites in women on Clomid therapy.	Clomiphene	92-98	progesterone receptor	Homo sapiens	63-65
9609574-0	1998	E-cadherin and its messenger ribonucleic acid in periimplantation phase human endometrium in normal and clomiphene-treated cycles.	Clomiphene	104-114	cadherin 1	Homo sapiens	0-10
9609574-1	1998	OBJECTIVE: The purpose of this investigation was to determine whether treatment with clomiphene citrate, which is estrogenic and antiestrogenic, affects the expression of the cell adhesion molecule E-cadherin in human periimplantation phase endometrium.	Clomiphene	85-103	cadherin 1	Homo sapiens	198-208
9609574-8	1998	The message for E-cadherin gene is expressed in endometrium of control (n = 5) and clomiphene cycles (n = 4).	Clomiphene	83-93	cadherin 1	Homo sapiens	16-26
8702220-5	1996	Tamoxifen, clomiphene, nafoxidine and ICI 182,780 significantly inhibited endothelial cell growth stimulated by bFGF and VEGF.	Clomiphene	11-21	vascular endothelial growth factor A	Homo sapiens	121-125
8781708-6	1996	Two estrogen receptor antagonists, tamoxifen and clomiphene, each restored monocyte chemotaxis to MCP-1 to control level, even in the presence of 17 beta-estradiol, suggesting that estrogen receptors are related to the effect of 17 beta-estradiol.	Clomiphene	49-59	C-C motif chemokine ligand 2	Homo sapiens	98-103
8582500-1	1995	OBJECTIVE: Guided by the favorable results of pulsatile gonadotrophin-releasing hormone (GnRH) in the recovery phase after GnRH agonist (GnRH-a) in PCOS, two hypotheses concerning the recovery phase were tested: (1) The resistance to clomiphene citrate will be broken in the recovery phase.	Clomiphene	234-252	gonadotropin releasing hormone 1	Homo sapiens	89-93
8749799-3	1995	EGF significantly enhanced P4, but not E2, secretion in human GC from clomiphene citrate (CC), human menopausal gonadotropin (hMG), and hMG/gonadotropin-releasing hormone agonist (GnRH-a)-treated patients.	Clomiphene	70-88	epidermal growth factor	Homo sapiens	0-3
7576116-0	1995	Early pregnancy factor (EPF) as a marker for detecting subclinical embryonic loss in clomiphene citrate-treated women.	Clomiphene	85-103	heat shock protein family E (Hsp10) member 1	Homo sapiens	24-27
7750589-0	1995	Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome.	Clomiphene	0-18	insulin like growth factor 1	Homo sapiens	33-61
7750589-0	1995	Clomiphene citrate reduces serum insulin-like growth factor I and increases sex hormone-binding globulin levels in women with polycystic ovary syndrome.	Clomiphene	0-18	sex hormone binding globulin	Homo sapiens	76-104
7750589-1	1995	OBJECTIVES: To evaluate the effect of clomiphene citrate (CC) on circulating levels of insulin-like growth factor I (IGF-I) and sex hormone-binding globulin (SHBG) in patients with polycystic ovary syndrome (PCOS).	Clomiphene	38-56	insulin like growth factor 1	Homo sapiens	87-115
7750589-1	1995	OBJECTIVES: To evaluate the effect of clomiphene citrate (CC) on circulating levels of insulin-like growth factor I (IGF-I) and sex hormone-binding globulin (SHBG) in patients with polycystic ovary syndrome (PCOS).	Clomiphene	38-56	insulin like growth factor 1	Homo sapiens	117-122
7750589-1	1995	OBJECTIVES: To evaluate the effect of clomiphene citrate (CC) on circulating levels of insulin-like growth factor I (IGF-I) and sex hormone-binding globulin (SHBG) in patients with polycystic ovary syndrome (PCOS).	Clomiphene	38-56	sex hormone binding globulin	Homo sapiens	128-156
7750589-1	1995	OBJECTIVES: To evaluate the effect of clomiphene citrate (CC) on circulating levels of insulin-like growth factor I (IGF-I) and sex hormone-binding globulin (SHBG) in patients with polycystic ovary syndrome (PCOS).	Clomiphene	38-56	sex hormone binding globulin	Homo sapiens	158-162
7576116-0	1995	Early pregnancy factor (EPF) as a marker for detecting subclinical embryonic loss in clomiphene citrate-treated women.	Clomiphene	85-103	heat shock protein family E (Hsp10) member 1	Homo sapiens	0-22
8584804-0	1995	Serum insulin in clomiphene responders and nonresponders with polycystic ovarian disease.	Clomiphene	17-27	insulin	Homo sapiens	6-13
8584804-1	1995	OBJECTIVE: To investigate insulin levels in women with polycystic ovarian disease (PCOD) who are responders or nonresponders to clomiphene citrate (CC).	Clomiphene	128-146	insulin	Homo sapiens	26-33
7947503-11	1994	When clomiphene was used for ovulation induction, women treated with hCG had a miscarriage rate of 14% compared with a rate 47% in women who received the placebo.	Clomiphene	5-15	chorionic gonadotropin subunit beta 5	Homo sapiens	69-72
7580013-1	1995	PURPOSE: This study was carried out to evaluate the potential role of the combination clomiphene citrate/human menopausal gonadotropin (CC/hMG) for patients who failed previous in vitro fertilization (IVF) attempts with gonadotropin-releasing hormone analogs (GnRH-a) and/or exogenous gonadotropins.	Clomiphene	86-104	gonadotropin releasing hormone 1	Homo sapiens	220-250
7860425-7	1994	The rate of increase in the E2/T ratio during clomiphene citrate treatment showed a statistically positive correlation (r = 0.542) with the rate of increase following hCG injection performed before clomiphene citrate treatment.	Clomiphene	46-64	hypertrichosis 2 (generalised, congenital)	Homo sapiens	167-170
7537976-5	1995	In the case of K36 and EL4 cells, inclusion of tamoxifen or clomiphene in the culture medium regularly caused the viable call count to fall below 20-30% of control in 36-48 h. Under these conditions, the addition of inhibitors of protein or RNA synthesis consistently increased viable cell count in a dose-dependent manner.	Clomiphene	60-70	epilepsy 4	Mus musculus	23-26
8193250-10	1994	Clomiphene does not increase LPD but increases serum progesterone, integrated progesterone, corpus luteum LH/human chorionic gonadotropin (hCG), and insulin-like growth factor-1 (IGF-1) receptors, all of which promote increased progesterone production and do not affect endometrial estrogen and progesterone receptors.	Clomiphene	0-10	insulin like growth factor 1	Homo sapiens	179-184
7914405-6	1994	Clomifene, nafoxidine and diethylstilbestrol also stimulated the Pgp ATPase activity, with maximal activations 75, 60 and 45% of the verapamil stimulation, respectively.	Clomiphene	0-9	ATP binding cassette subfamily B member 1	Homo sapiens	65-68
8034070-2	1994	STUDY DESIGN: The number of doublings of hCG per day (1/DT; reciprocal of hCG doubling time) was correlated with serum P using linear and nonlinear models in normal intrauterine pregnancies, spontaneous abortions, and ectopic pregnancies (EPs) conceived spontaneously or after clomiphene citrate (CC).	Clomiphene	277-295	hypertrichosis 2 (generalised, congenital)	Homo sapiens	41-44
8147231-7	1993	The addition of hCG augmented steroidogenesis in all groups at all concentrations, but this still remained lower in all clomiphene citrate-treated groups compared to controls.	Clomiphene	120-138	chorionic gonadotropin subunit beta 5	Homo sapiens	16-19
8187300-12	1994	Mean level of ET1-21 or ET-1,2 was significantly lower in patients treated empirically with clomiphene citrate or gonadotrophins (n = 34) compared to untreated (n = 52) patients (P = 0.04).	Clomiphene	92-110	endothelin 1	Homo sapiens	14-20
1619610-1	1992	Nine patients with clomiphene-resistant polycystic ovary disease (PCOD) were treated with pulsatile gonadotropin releasing hormone (GnRH).	Clomiphene	19-29	gonadotropin releasing hormone 1	Homo sapiens	100-130
8133215-5	1993	The immunosuppressive OE2 effect is associated with a 16-fold increase in the circulating level of OE2 and can be prevented by ER blockers such as tamoxifen and clomifene.	Clomiphene	161-170	early B cell factor 3	Mus musculus	22-25
8133215-5	1993	The immunosuppressive OE2 effect is associated with a 16-fold increase in the circulating level of OE2 and can be prevented by ER blockers such as tamoxifen and clomifene.	Clomiphene	161-170	early B cell factor 3	Mus musculus	99-102
8215694-0	1993	Changes in seminal plasma transferrin concentration following administration of clomiphene citrate.	Clomiphene	80-98	transferrin	Homo sapiens	26-37
7685718-1	1993	OBJECTIVE: To study the serum levels of insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor binding protein-1 (IGFBP-1) in relation to clomiphene citrate (CC) responsiveness in women with polycystic ovarian disease (PCOD).	Clomiphene	161-179	insulin	Homo sapiens	40-47
7685718-1	1993	OBJECTIVE: To study the serum levels of insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor binding protein-1 (IGFBP-1) in relation to clomiphene citrate (CC) responsiveness in women with polycystic ovarian disease (PCOD).	Clomiphene	161-179	insulin like growth factor 1	Homo sapiens	49-77
7685718-1	1993	OBJECTIVE: To study the serum levels of insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor binding protein-1 (IGFBP-1) in relation to clomiphene citrate (CC) responsiveness in women with polycystic ovarian disease (PCOD).	Clomiphene	161-179	insulin like growth factor 1	Homo sapiens	79-84
7685718-1	1993	OBJECTIVE: To study the serum levels of insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor binding protein-1 (IGFBP-1) in relation to clomiphene citrate (CC) responsiveness in women with polycystic ovarian disease (PCOD).	Clomiphene	161-179	insulin like growth factor binding protein 1	Homo sapiens	91-135
7685718-1	1993	OBJECTIVE: To study the serum levels of insulin, insulin-like growth factor I (IGF-I), and insulin-like growth factor binding protein-1 (IGFBP-1) in relation to clomiphene citrate (CC) responsiveness in women with polycystic ovarian disease (PCOD).	Clomiphene	161-179	insulin like growth factor binding protein 1	Homo sapiens	137-144
1535603-1	1992	Meta-analysis of all randomised trials published so far, was performed to compare the effect of additional gonadotropin releasing hormone (GnRH)-agonist treatment to exogenous gonadotropins for ovulation induction in clomiphene-resistant polycystic ovary syndrome (PCOS) patients.	Clomiphene	217-227	gonadotropin releasing hormone 1	Homo sapiens	139-143
1502933-8	1992	The response to hCG was maximal on day 4 for the clomiphene citrate- and Leu-S-treated cells, while the rest of the protocols had a peak on day 6.	Clomiphene	49-67	chorionic gonadotropin subunit beta 5	Homo sapiens	16-19
1619610-1	1992	Nine patients with clomiphene-resistant polycystic ovary disease (PCOD) were treated with pulsatile gonadotropin releasing hormone (GnRH).	Clomiphene	19-29	gonadotropin releasing hormone 1	Homo sapiens	132-136
1619610-9	1992	These data suggest that ovulation and conception in clomiphene-resistant PCOD patients using pulsatile GnRH are more likely to occur after IV than SC administration.	Clomiphene	52-62	gonadotropin releasing hormone 1	Homo sapiens	103-107
1582522-16	1992	Subcutaneous pulsatile LHRH therapy may be effective for the induction of ovulation in clomiphene-resistant hypothalamic amenorrhea; however, it will be necessary to solve the problem of dosage and the interval of LHRH administration in the future.	Clomiphene	87-97	gonadotropin releasing hormone 1	Homo sapiens	23-27
1303923-0	1992	[Use of GnRH analog for induction of gonadotropin ovulatory surge in cycles stimulated by clomiphene citrate and menopausal gonadotropin in an in vitro fertilization program].	Clomiphene	90-108	gonadotropin releasing hormone 1	Homo sapiens	8-12
1303923-2	1992	The authors showed that a single injection of GnRH analogue in the cycles stimulated with clomiphene citrate and menopausal gonadotropin causes pituitary output of both LH and FSH which is sufficient for morphological and functional maturity of the oocytes.	Clomiphene	90-108	gonadotropin releasing hormone 1	Homo sapiens	46-50
1576272-4	1992	Clomiphene, administered in the hours preceding decidual induction, inhibited the increase of ornithine decarboxylase activity, which normally marks the end of the induction phase.	Clomiphene	0-10	ornithine decarboxylase 1	Rattus norvegicus	94-117
1582522-16	1992	Subcutaneous pulsatile LHRH therapy may be effective for the induction of ovulation in clomiphene-resistant hypothalamic amenorrhea; however, it will be necessary to solve the problem of dosage and the interval of LHRH administration in the future.	Clomiphene	87-97	gonadotropin releasing hormone 1	Homo sapiens	214-218
1757515-0	1991	Effect of clomiphene citrate on the synthesis and release of the human beta-lactoglobulin homologue, pregnancy associated endometrial alpha 2-globulin, by the uterine endometrium.	Clomiphene	10-28	progestagen associated endometrial protein	Homo sapiens	101-150
1576983-8	1992	When using hMG or pulsatile GnRH in clomiphene-resistant patients, pretreatment with GnRH analogs may normalize their response and result in higher pregnancy rates.	Clomiphene	36-46	gonadotropin releasing hormone 1	Homo sapiens	28-32
1576983-8	1992	When using hMG or pulsatile GnRH in clomiphene-resistant patients, pretreatment with GnRH analogs may normalize their response and result in higher pregnancy rates.	Clomiphene	36-46	gonadotropin releasing hormone 1	Homo sapiens	85-89
1805541-0	1991	Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat.	Clomiphene	22-40	gonadotropin releasing hormone 1	Rattus norvegicus	87-91
1909978-1	1991	STUDY OBJECTIVE: To determine if gonadotropin-releasing hormone agonist (GnRH-a) and gonadotropin therapy could improve folliculogenesis and pregnancy rates (PRs) in women with a previously satisfactory response to clomiphene citrate and human menopausal gonadotropin (hMG).	Clomiphene	215-233	gonadotropin releasing hormone 1	Homo sapiens	33-63
1838308-2	1991	Antiestrogenic agents, clomiphene and tamoxifen, inhibited the PKC-dependent phosphorylation of histone and r-annexin I in a dose-dependent manner.	Clomiphene	23-33	annexin A1	Rattus norvegicus	110-119
1906682-0	1991	Effect of clomiphene citrate treatment on endometrial estrogen and progesterone receptor induction in women.	Clomiphene	10-28	progesterone receptor	Homo sapiens	67-88
1936328-1	1991	OBJECTIVE: To report a preliminary study on the efficacy of a gonadotropin-releasing hormone antagonist (Nal-Glu) for preventing premature luteinizing hormone (LH) and progesterone (P) rise in controlled ovarian hyperstimulation using clomiphene citrate (CC) and human menopausal gonadotropin (hMG).	Clomiphene	235-253	gonadotropin releasing hormone 1	Homo sapiens	62-92
2108987-1	1990	The effect of clomiphene on the pituitary response to exogenous LHRH was investigated in five hypogonadal women during long-term treatment with varying doses of oestrogen.	Clomiphene	14-24	gonadotropin releasing hormone 1	Homo sapiens	64-68
1752604-2	1991	A transient increase in serum PRL at the ovulatory phase was found in about half of the IVF-ET patients during clomiphene stimulation, and increased levels of PRL in serum and follicular fluid at the ovulatory phase may suppress the fertilization and cleavage of oocytes.	Clomiphene	111-121	prolactin	Homo sapiens	30-33
2240131-1	1990	Pulsatile administration of gonadotropin-releasing hormone represents a major advance in the treatment of anovulation in women who fail to ovulate with clomiphene citrate and is an alternative for many women who currently receive human menopausal gonadotropin.	Clomiphene	152-170	gonadotropin releasing hormone 1	Homo sapiens	28-58
2240131-7	1990	Pulsatile gonadotropin-releasing hormone therapy is a safe, effective, convenient, and economical alternative to human menopausal gonadotropin for ovulation induction in women resistant to clomiphene.	Clomiphene	189-199	gonadotropin releasing hormone 1	Homo sapiens	10-40
2282743-1	1990	The use of pulsatile GnRH to treat infertile women who do not ovulate has been shown to be safe, simple, and effective and the preferred method of inducing ovulation in appropriately selected patients who are resistant to treatment with clomiphene citrate.	Clomiphene	237-255	gonadotropin releasing hormone 1	Homo sapiens	21-25
2221814-2	1990	In clomiphene citrate (CC) nonresponsive cases of polycystic ovarian disease (PCOD), the major advantage of pulsatile LHRH is that when ovulation occurs, it is usually uni-follicular.	Clomiphene	3-21	gonadotropin releasing hormone 1	Homo sapiens	118-122
2360588-1	1990	Elevated levels of serum and follicular fluid prolactin occur in women undergoing ovulation induction with both clomiphene citrate and gonadotropin therapy.	Clomiphene	112-130	prolactin	Homo sapiens	46-55
2140335-0	1990	[Dehydroepiandrosterone sulfate (DHEAS) concentration changes in clomiphene therapy?].	Clomiphene	65-75	sulfotransferase family 2A member 1	Homo sapiens	33-38
2140335-1	1990	Plasma DHEAS levels were followed in 10 anovulatory patients, treated with 50 mg clomiphene citrate from the 5th to the 9th day of menstruation as well as 6 ovulatory women, who were taken as controls.	Clomiphene	81-99	sulfotransferase family 2A member 1	Homo sapiens	7-12
2108987-3	1990	Clomiphene augmented the LH and FSH response to LHRH (an acute i.v.	Clomiphene	0-10	gonadotropin releasing hormone 1	Homo sapiens	48-52
2108987-5	1990	We conclude that clomiphene exerts anti-oestrogenic effects on basal and LHRH-stimulated release of gonadotrophins in hypogonadal women during long-term treatment with oestrogen.	Clomiphene	17-27	gonadotropin releasing hormone 1	Homo sapiens	73-77
34743357-1	2022	WHAT IS KNOWN AND OBJECTIVE: Although several clinical trials have compared the clinical efficacy of clomiphene citrate (CC) combined with metformin (MET) in the treatment of women with polycystic ovary syndrome (PCOS), the results are controversial.	Clomiphene	101-119	SAFB like transcription modulator	Homo sapiens	150-153
778710-0	1976	The effect of L-dopa and clomiphene citrate on peripheral plasma levels of luteinizing hormone-releasing factor.	Clomiphene	25-43	CREB3 regulatory factor	Homo sapiens	75-111
778710-1	1976	Response of luteinizing hormone-releasing factor (LRF) and gonadotropin levels to orally administered L-dopa and clomiphene citrate were measured in 13 healthy female volunteers.	Clomiphene	113-131	CREB3 regulatory factor	Homo sapiens	12-48
2136015-6	1990	17 beta-estradiol (10(-5) M), clomiphene citrate (10(-5) M), and o,p-DDT (10(-5)) significantly inhibited hCG-supported P production by human cumulus cells in vitro.	Clomiphene	30-48	chorionic gonadotropin subunit beta 5	Homo sapiens	106-109
34813001-0	2022	The regulatory effects of clomiphene and tamoxifen on mTOR and LC3-II expressions in relation to autophagy in experimental polycystic ovary syndrome (PCOS).	Clomiphene	26-36	mechanistic target of rapamycin kinase	Rattus norvegicus	54-58
34813001-0	2022	The regulatory effects of clomiphene and tamoxifen on mTOR and LC3-II expressions in relation to autophagy in experimental polycystic ovary syndrome (PCOS).	Clomiphene	26-36	annexin A3	Rattus norvegicus	63-66
2507780-9	1989	It appears that hMG-S treatment can improve ovarian function and achieve successful pregnancy in patients with luteal phase defects who fail to produce a live birth during clomiphene treatment.	Clomiphene	172-182	MGS	Homo sapiens	16-21
34690927-0	2021	Could Cytochrome P450 2D6, 3A4 and 3A5 Polymorphisms Explain the Variability in Clinical Response to Clomiphene Citrate of Anovulatory PCOS Women?	Clomiphene	101-119	cytochrome P450 2D6	Homo sapiens	6-25
34540296-3	2021	Clomiphene citrate is a selective estrogen receptor modulator, approved for treating infertility in females, but is being used as an off-label therapy in treating male hypogonadism.	Clomiphene	0-18	estrogen receptor 1	Homo sapiens	34-51
34483894-17	2021	Statistically significant increased sperm parameters were noted in combinations of zinc sulfate (220 mg BID), clomiphene citrate (50 mg BID), and testosterone undecanoate and CoQ10; tamoxifen citrate and FSH were shown to improve the hormonal profile in infertile males.	Clomiphene	110-128	BH3 interacting domain death agonist	Homo sapiens	136-139
34278201-1	2021	Background: Clomiphene citrate is an estrogen receptor ligand with mixed agonistic-antagonistic properties used for the treatment of female and male infertility.	Clomiphene	12-30	estrogen receptor 1	Homo sapiens	37-54
34316229-0	2021	Reduced Angiopoietin-2 as a Predictive Biomarker for Clomiphene Citrate Resistance in Polycystic Ovary Syndrome.	Clomiphene	53-71	angiopoietin 2	Homo sapiens	8-22
35513593-8	2022	Clomiphene treatment increased mRNA expression of Bax (4 fold) and SOD-2 (2 fold), which was reversed by co-treatment with estradiol.	Clomiphene	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	50-53
35513593-8	2022	Clomiphene treatment increased mRNA expression of Bax (4 fold) and SOD-2 (2 fold), which was reversed by co-treatment with estradiol.	Clomiphene	0-10	superoxide dismutase 2	Homo sapiens	67-72
34872312-8	2021	RESULTS: Serum IL-23 levels showed no statistically significant difference between the clomiphene-sensitive and the clomiphene-resistant groups, whereas MCP-1, TNF-alpha, angiopoietin-2, and adiponectin levels were significantly different between the two groups (all P<0.05).	Clomiphene	116-126	tumor necrosis factor	Homo sapiens	160-169
34872312-8	2021	RESULTS: Serum IL-23 levels showed no statistically significant difference between the clomiphene-sensitive and the clomiphene-resistant groups, whereas MCP-1, TNF-alpha, angiopoietin-2, and adiponectin levels were significantly different between the two groups (all P<0.05).	Clomiphene	116-126	angiopoietin 2	Homo sapiens	171-185
34872312-8	2021	RESULTS: Serum IL-23 levels showed no statistically significant difference between the clomiphene-sensitive and the clomiphene-resistant groups, whereas MCP-1, TNF-alpha, angiopoietin-2, and adiponectin levels were significantly different between the two groups (all P<0.05).	Clomiphene	116-126	adiponectin, C1Q and collagen domain containing	Homo sapiens	191-202
34872312-9	2021	Univariate logistic regression analysis indicated that elevated serum TNF-alpha (odds ratio (OR) =1.88, P<0.001), decreased angiopoietin-2 (OR =0.61, P=0.007), and adiponectin (OR =0.39, P=0.012) levels were significantly associated with clomiphene resistance.	Clomiphene	238-248	tumor necrosis factor	Homo sapiens	70-79
34872312-9	2021	Univariate logistic regression analysis indicated that elevated serum TNF-alpha (odds ratio (OR) =1.88, P<0.001), decreased angiopoietin-2 (OR =0.61, P=0.007), and adiponectin (OR =0.39, P=0.012) levels were significantly associated with clomiphene resistance.	Clomiphene	238-248	angiopoietin 2	Homo sapiens	124-138
34872312-9	2021	Univariate logistic regression analysis indicated that elevated serum TNF-alpha (odds ratio (OR) =1.88, P<0.001), decreased angiopoietin-2 (OR =0.61, P=0.007), and adiponectin (OR =0.39, P=0.012) levels were significantly associated with clomiphene resistance.	Clomiphene	238-248	adiponectin, C1Q and collagen domain containing	Homo sapiens	164-175
34872312-10	2021	The sensitivity of TNF-alpha and angiopoietin-2 to distinguish clomiphene resistance in patients with PCOS was 100%.	Clomiphene	63-73	tumor necrosis factor	Homo sapiens	19-28
34872312-10	2021	The sensitivity of TNF-alpha and angiopoietin-2 to distinguish clomiphene resistance in patients with PCOS was 100%.	Clomiphene	63-73	angiopoietin 2	Homo sapiens	33-47
34872312-11	2021	Moreover, the diagnostic efficiency of TNF-alpha and adiponectin in identifying clomiphene resistance was significantly higher than that of MCP-1 and angiopoietin-2 (all P<0.05).	Clomiphene	80-90	tumor necrosis factor	Homo sapiens	39-48
34872312-11	2021	Moreover, the diagnostic efficiency of TNF-alpha and adiponectin in identifying clomiphene resistance was significantly higher than that of MCP-1 and angiopoietin-2 (all P<0.05).	Clomiphene	80-90	adiponectin, C1Q and collagen domain containing	Homo sapiens	53-64
34872312-12	2021	CONCLUSIONS: Abnormal TNF-alpha, angiopoietin-2, and adiponectin levels may be associated with clomiphene resistance in PCOS patients.	Clomiphene	95-105	tumor necrosis factor	Homo sapiens	22-31
34872312-12	2021	CONCLUSIONS: Abnormal TNF-alpha, angiopoietin-2, and adiponectin levels may be associated with clomiphene resistance in PCOS patients.	Clomiphene	95-105	angiopoietin 2	Homo sapiens	33-47
34872312-12	2021	CONCLUSIONS: Abnormal TNF-alpha, angiopoietin-2, and adiponectin levels may be associated with clomiphene resistance in PCOS patients.	Clomiphene	95-105	adiponectin, C1Q and collagen domain containing	Homo sapiens	53-64
34872312-13	2021	The serum proinflammatory cytokines TNF-alpha and adiponectin are helpful discriminators of clomiphene resistance in PCOS patients.	Clomiphene	92-102	tumor necrosis factor	Homo sapiens	36-45
34872312-13	2021	The serum proinflammatory cytokines TNF-alpha and adiponectin are helpful discriminators of clomiphene resistance in PCOS patients.	Clomiphene	92-102	adiponectin, C1Q and collagen domain containing	Homo sapiens	50-61
34465847-7	2021	Endometrial preparation protocols using clomiphene (CC) were associated with a significantly increased risk for EP (1.12%, adjusted OR = 2.34; 95% CI, 1.38 to 3.98).	Clomiphene	40-50	epiregulin	Homo sapiens	112-114
2513393-4	1989	The response of both FSH and LH to LHRH showed a significant and quantitatively similar decrease during clomiphene or FSH administration as compared to the spontaneous cycles.	Clomiphene	104-114	gonadotropin releasing hormone 1	Homo sapiens	35-39
2680614-1	1989	Nine clomiphene citrate-resistant polycystic ovarian disease (PCOD) patients received intravenous gonadotropin-releasing hormone (GnRH) pulses before and immediately after 1 month of GnRH agonist (GnRH-a) therapy.	Clomiphene	5-23	gonadotropin releasing hormone 1	Homo sapiens	98-128
2569927-0	1989	Induction and promotion of gamma-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations.	Clomiphene	130-140	gamma-glutamyltransferase 1	Rattus norvegicus	27-55
2571598-3	1989	Clomiphene stimulated progesterone production in both the presence and absence of additional hCG at concentrations less than or equal to 10(7) M. In both the presence and absence of hCG a dose-dependent inhibition of progesterone production was observed with higher concentrations of clomiphene (greater than 10(6) M).	Clomiphene	0-10	hypertrichosis 2 (generalised, congenital)	Homo sapiens	182-185
2571598-3	1989	Clomiphene stimulated progesterone production in both the presence and absence of additional hCG at concentrations less than or equal to 10(7) M. In both the presence and absence of hCG a dose-dependent inhibition of progesterone production was observed with higher concentrations of clomiphene (greater than 10(6) M).	Clomiphene	284-294	hypertrichosis 2 (generalised, congenital)	Homo sapiens	182-185
2571598-4	1989	hCG (1 IU/mL) significantly increased progesterone production in control cells and at all concentrations of clomiphene (10(-9)-10(-5) M) tested.	Clomiphene	108-118	hypertrichosis 2 (generalised, congenital)	Homo sapiens	0-3
2512039-0	1989	The role of chronic anovulation in the polycystic ovary syndrome: normalization of sex-hormone-binding globulin levels after clomiphene-induced ovulation.	Clomiphene	125-135	sex hormone binding globulin	Homo sapiens	83-111
2512039-4	1989	After two cycles of clomiphene-induced ovulation, the serum LH concentration fell significantly and levels of SHBG increased significantly to levels similar to those found in spontaneously ovulating women with normal ovaries.	Clomiphene	20-30	sex hormone binding globulin	Homo sapiens	110-114
2491993-0	1989	Ovulation induction with pulsatile luteinizing hormone-releasing hormone in women with clomiphene citrate-resistant polycystic ovary-like disease: endocrine results.	Clomiphene	87-105	gonadotropin releasing hormone 1	Homo sapiens	35-72
3134777-8	1988	In summary, 1) reproductive function was compromised by clomiphene and many responses were age-dependent, 2) reductions in gonadotropins suggest that clomiphene decreased their synthesis and/or release, and 3) decreased serum LH and testicular LH receptor concentrations were coupled to reduced testosterone secretion.	Clomiphene	150-160	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	244-255
3569554-0	1987	Estrogen receptor binding material in blood of patients after clomiphene citrate administration: determination by a radioreceptor assay.	Clomiphene	62-80	estrogen receptor 1	Homo sapiens	0-17
3281077-0	1988	The efficacy of every-other-day administration of gonadotropin-releasing hormone in women with hypothalamic amenorrhea: gonadotropin-releasing hormone treatment can induce clomiphene responsiveness.	Clomiphene	172-182	gonadotropin releasing hormone 1	Homo sapiens	50-80
3281077-0	1988	The efficacy of every-other-day administration of gonadotropin-releasing hormone in women with hypothalamic amenorrhea: gonadotropin-releasing hormone treatment can induce clomiphene responsiveness.	Clomiphene	172-182	gonadotropin releasing hormone 1	Homo sapiens	120-150
3281077-1	1988	The efficacy of every-other-day gonadotropin-releasing hormone administration was investigated in clomiphene-human chorionic gonadotropin (hCG) resistant, anovulatory women with hypogonadotropism or normogonadotropism.	Clomiphene	98-108	gonadotropin releasing hormone 1	Homo sapiens	32-62
3281077-1	1988	The efficacy of every-other-day gonadotropin-releasing hormone administration was investigated in clomiphene-human chorionic gonadotropin (hCG) resistant, anovulatory women with hypogonadotropism or normogonadotropism.	Clomiphene	98-108	chorionic gonadotropin subunit beta 5	Homo sapiens	139-142
3281077-5	1988	Among eight normogonadotropic women, four with amenorrhea of one year or less became clomiphene-hCG responders after one or two courses of gonadotropin-releasing hormone treatment.	Clomiphene	85-95	chorionic gonadotropin subunit beta 5	Homo sapiens	96-99
3281077-8	1988	We conclude that intramuscular gonadotropin-releasing hormone treatment is effective in inducing responsiveness to clomiphene, especially in hypogonadotropic anovulatory women.	Clomiphene	115-125	gonadotropin releasing hormone 1	Homo sapiens	31-61
3281655-1	1988	The potentiation of glucose-stimulated insulin release induced by 100 nM-12-O-tetradecanoylphorbol 13-acetate (TPA) was inhibited by clomiphene, an inhibitor of protein kinase C (PK C), in a dose-dependent manner.	Clomiphene	133-143	protein kinase C, gamma	Rattus norvegicus	161-177
3281655-1	1988	The potentiation of glucose-stimulated insulin release induced by 100 nM-12-O-tetradecanoylphorbol 13-acetate (TPA) was inhibited by clomiphene, an inhibitor of protein kinase C (PK C), in a dose-dependent manner.	Clomiphene	133-143	protein kinase C, gamma	Rattus norvegicus	179-183
3130452-1	1988	The diagnostic response toward the administration of a luteinizing hormone-releasing hormone (LH-RH) analogue in the early follicular phase has been used sequentially with conventional human menopausal gonadotropin (hMG) treatment in patients who had previously failed to develop multiple follicles in response to a combination of hMG and clomiphene citrate.	Clomiphene	339-357	gonadotropin releasing hormone 1	Homo sapiens	55-92
3130452-1	1988	The diagnostic response toward the administration of a luteinizing hormone-releasing hormone (LH-RH) analogue in the early follicular phase has been used sequentially with conventional human menopausal gonadotropin (hMG) treatment in patients who had previously failed to develop multiple follicles in response to a combination of hMG and clomiphene citrate.	Clomiphene	339-357	gonadotropin releasing hormone 1	Homo sapiens	94-99
3595903-5	1987	The production of embryo-derived PAF was related to the type of treatment used to induce follicular development (with clomiphene citrate and human menopausal gonadotropin commencing on day 5 giving best results); the size and estradiol production of the follicles producing the embryo; the age of the embryo culture medium; and the morphology and cell number of the embryos.	Clomiphene	118-136	PCNA clamp associated factor	Homo sapiens	33-36
3665121-8	1987	In castrated men, fenfluramine is also able to enhance PRL secretion but to a lesser extent; after clomiphene citrate treatment the increase of plasma PRL levels induced by fenfluramine rises to the normal range.	Clomiphene	99-117	prolactin	Homo sapiens	151-154
2885281-0	1987	Prolactin response to clomiphene citrate is different in hyperprolactinemic polycystic ovary syndrome and idiopathic hyperprolactinemia.	Clomiphene	22-40	prolactin	Homo sapiens	0-9
3098102-0	1986	Human chorionic gonadotropin reduces aromatizable androgens and aromatase activity in women stimulated by clomiphene citrate and human menopausal gonadotropin.	Clomiphene	106-124	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	64-73
3298470-1	1987	Seven clomiphene-resistant normoprolactinemic anovulatory patients were treated with GnRH pulsatile administration (total 15 treatment cycles).	Clomiphene	6-16	gonadotropin releasing hormone 1	Homo sapiens	85-89
3106096-0	1987	Evidence against the involvement of opiate neurons in mediating the effect of clomiphene citrate on gonadotropin-releasing hormone neurons.	Clomiphene	78-96	gonadotropin releasing hormone 1	Homo sapiens	100-130
3106096-1	1987	This study was designed to assess whether the hypothalamic action of clomiphene citrate (CC) on gonadotropin-releasing hormone (GnRH) neurons required activity of opiate neurons.	Clomiphene	69-87	gonadotropin releasing hormone 1	Homo sapiens	96-126
3106096-1	1987	This study was designed to assess whether the hypothalamic action of clomiphene citrate (CC) on gonadotropin-releasing hormone (GnRH) neurons required activity of opiate neurons.	Clomiphene	69-87	gonadotropin releasing hormone 1	Homo sapiens	128-132
3136067-1	1987	The long-acting agonist analogue of LHRH, Buserelin (Hoechst) has been used to suppress endogenous gonadotrophins prior to induction of ovulation with low dose human menopausal gonadotrophin (HMG) in women with clomiphene-resistant polycystic ovary syndrome (PCOS).	Clomiphene	211-221	gonadotropin releasing hormone 1	Homo sapiens	36-40
3098102-7	1986	Thus human chorionic gonadotropin, which triggers ovulation in women treated by clomiphene citrate-human menopausal gonadotropin, appears to partially reduce aromatizable substrate as well as inhibit aromatase activity.	Clomiphene	80-98	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	200-209
3091237-3	1986	hMG in conjunction with clomiphene citrate did not suppress the endogenous LH surge but enhanced the oestradiol levels in the 2 days prior to hCG administration and/or the onset of the LH surge.	Clomiphene	24-42	hypertrichosis 2 (generalised, congenital)	Homo sapiens	142-145
2946978-3	1986	After hyperstimulation with clomiphene and gonadotropin for in vitro fertilization, the mean concentrations of beta-E and beta-LPH in follicular fluid did not increase significantly, being 3.2 +/- 0.6 and 4.1 +/- 1.0 pmol/l, respectively (N=13).	Clomiphene	28-38	proopiomelanocortin	Homo sapiens	111-117
2946978-3	1986	After hyperstimulation with clomiphene and gonadotropin for in vitro fertilization, the mean concentrations of beta-E and beta-LPH in follicular fluid did not increase significantly, being 3.2 +/- 0.6 and 4.1 +/- 1.0 pmol/l, respectively (N=13).	Clomiphene	28-38	proopiomelanocortin	Homo sapiens	122-130
3789035-0	1986	Effects of clomiphene citrate on cytosolic estradiol and progesterone receptor concentrations in secretory endometrium.	Clomiphene	11-29	progesterone receptor	Homo sapiens	57-78
3789035-2	1986	Clomiphene citrate treatment (250 to 750 mg per cycle) decreased both endometrial estradiol and progesterone receptor concentrations.	Clomiphene	0-18	progesterone receptor	Homo sapiens	96-117
3789035-5	1986	Steroid receptor concentrations correlated negatively with the duration of clomiphene citrate therapy, which implies a time-dependent suppressive effect of clomiphene citrate on measurable cytosolic estradiol and progesterone receptor concentrations during the luteal phase of the cycle.	Clomiphene	75-93	progesterone receptor	Homo sapiens	213-234
3789035-5	1986	Steroid receptor concentrations correlated negatively with the duration of clomiphene citrate therapy, which implies a time-dependent suppressive effect of clomiphene citrate on measurable cytosolic estradiol and progesterone receptor concentrations during the luteal phase of the cycle.	Clomiphene	156-174	progesterone receptor	Homo sapiens	213-234
3094308-11	1986	Clomiphene raised the LRH-stimulated (not the autonomous) secretion of LH and FSH.	Clomiphene	0-10	gonadotropin releasing hormone 1	Rattus norvegicus	22-25
3094308-13	1986	Clomiphene also raised the LRH-stimulated secretion of LH and FSH after pre-treatment with LRH, but OB did not do so: LRH prevented the stimulatory effect of OB but not of clomiphene.	Clomiphene	0-10	gonadotropin releasing hormone 1	Rattus norvegicus	27-30
3094308-13	1986	Clomiphene also raised the LRH-stimulated secretion of LH and FSH after pre-treatment with LRH, but OB did not do so: LRH prevented the stimulatory effect of OB but not of clomiphene.	Clomiphene	0-10	gonadotropin releasing hormone 1	Rattus norvegicus	91-94
3094308-13	1986	Clomiphene also raised the LRH-stimulated secretion of LH and FSH after pre-treatment with LRH, but OB did not do so: LRH prevented the stimulatory effect of OB but not of clomiphene.	Clomiphene	0-10	gonadotropin releasing hormone 1	Rattus norvegicus	91-94
3716757-10	1986	A single ip injection of 250 micrograms clomiphene citrate (clomiphene) significantly reduced both the pituitary weight and PgR concentration in these animals, but 1 mg of Dex failed to have a similar effect.	Clomiphene	40-58	progesterone receptor	Rattus norvegicus	124-127
3716757-10	1986	A single ip injection of 250 micrograms clomiphene citrate (clomiphene) significantly reduced both the pituitary weight and PgR concentration in these animals, but 1 mg of Dex failed to have a similar effect.	Clomiphene	40-50	progesterone receptor	Rattus norvegicus	124-127
3515262-2	1986	This method of evaluating ovarian steroid production provided a convenient, inexpensive, and noninvasive means of monitoring responses to gonadotropin-releasing hormone treatments and documents that clomiphene-resistant amenorrheic patients can be induced to ovulate with appropriate gonadotropin-releasing hormone therapy.	Clomiphene	199-209	gonadotropin releasing hormone 1	Homo sapiens	138-168
3515262-2	1986	This method of evaluating ovarian steroid production provided a convenient, inexpensive, and noninvasive means of monitoring responses to gonadotropin-releasing hormone treatments and documents that clomiphene-resistant amenorrheic patients can be induced to ovulate with appropriate gonadotropin-releasing hormone therapy.	Clomiphene	199-209	gonadotropin releasing hormone 1	Homo sapiens	284-314
3080347-1	1986	Fifteen ovulatory patients undergoing ovarian stimulation with clomiphene citrate-human menopausal gonadotropin-human chorionic gonadotropin (hCG) for in vitro fertilization were studied.	Clomiphene	63-81	chorionic gonadotropin subunit beta 5	Homo sapiens	99-146
3455681-2	1986	TAM (100 microM) and CLO (100 microM) completely blocked PTH (2 nM)-induced resorption; 10 microM TAM was ineffective in blocking resorption, while 40-50 microM partially inhibited the response.	Clomiphene	21-24	parathyroid hormone	Homo sapiens	57-60
3935867-5	1985	In experimental hyperprolactinemia, GnRH induced a near normal LH response but caused an exaggerated FSH response, which was normalized after clomiphene treatment.	Clomiphene	142-152	gonadotropin releasing hormone 1	Homo sapiens	36-40
16867619-2	1986	The isomers of clomiphene, in addition to metabolites, are extracted from plasma with tert-butyl methyl ether (MTB).	Clomiphene	15-25	metallothionein 1J, pseudogene	Homo sapiens	111-114
3937739-0	1985	Basal prolactin and the behaviour of the gonadotrophins, testosterone, androstenedione, estradiol, and the sex-hormone-binding globulin during stimulation with clomiphene in subjects with spermatogenic disorders.	Clomiphene	160-170	sex hormone binding globulin	Homo sapiens	107-135
3934371-0	1985	Potentiation of GnRH response by clomiphene citrate.	Clomiphene	33-51	gonadotropin releasing hormone 1	Homo sapiens	16-20
3926532-0	1985	Clomiphene citrate can mimic the augmentative (positive) but not the depressing (negative) effect of estradiol on the LHRH-stimulated release of LH and FSH by the pituitary gland of the long-term ovariectomized rat.	Clomiphene	0-18	gonadotropin releasing hormone 1	Rattus norvegicus	118-122
3841376-9	1985	Treatment of castrated mice with 17-beta-estradiol increased the HDC activity of the kidney, and this increase was antagonized by concomitant treatment with clomiphene, an antiestrogen, confirming that the increase is mediated through an estrogen receptor.	Clomiphene	157-167	histidine decarboxylase	Mus musculus	65-68
3926532-1	1985	In the long-term ovariectomized rat, both estradiol benzoate (EB) and clomiphene citrate enhance the release of LH induced by luteinizing hormone-releasing hormone (LHRH).	Clomiphene	70-88	gonadotropin releasing hormone 1	Rattus norvegicus	126-163
3926532-1	1985	In the long-term ovariectomized rat, both estradiol benzoate (EB) and clomiphene citrate enhance the release of LH induced by luteinizing hormone-releasing hormone (LHRH).	Clomiphene	70-88	gonadotropin releasing hormone 1	Rattus norvegicus	165-169
3884647-5	1985	After the patient was treated with clomiphene for 4 months, her menses resumed, hair growth slowed, fasting blood glucose and plasma insulin concentrations decreased, and serum inhibitory activity decreased to the control range.	Clomiphene	35-45	insulin	Homo sapiens	133-140
3931501-0	1985	Effects of experimental hyperprolactinemia and clomiphene on pituitary responsiveness to LHRH and TRH in men.	Clomiphene	47-57	gonadotropin releasing hormone 1	Homo sapiens	89-93
3995129-1	1985	Concentrations of human prolactin (hPrl) greater than or equal to 600 ng/ml produced inhibition of progestin production in cultures of granulosa cells pooled from follicles of women stimulated with clomiphene citrate-human chorionic gonadotropin (hCG).	Clomiphene	198-216	prolactin	Homo sapiens	24-33
3995129-1	1985	Concentrations of human prolactin (hPrl) greater than or equal to 600 ng/ml produced inhibition of progestin production in cultures of granulosa cells pooled from follicles of women stimulated with clomiphene citrate-human chorionic gonadotropin (hCG).	Clomiphene	198-216	prolactin	Homo sapiens	35-39
3976792-3	1985	In the present study the prolactin production by explants of normal, luteal phase defective, progesterone-corrected luteal phase defective, and clomiphene- or follicle-stimulating hormone/luteinizing hormone-corrected luteal phase defective late secretory endometrium was measured over 96 hours at 24-hour intervals.	Clomiphene	144-154	prolactin	Homo sapiens	25-34
3917407-1	1985	Seventy-three treatment courses of pulsatile gonadotropin-releasing hormone (GnRH) were given to 19 patients with clomiphene nonresponsive anovulatory infertility.	Clomiphene	114-124	gonadotropin releasing hormone 1	Homo sapiens	45-75
3155698-2	1985	This study was carried out to determine whether the ovulatory response with clomiphene citrate (CC) in patients with elevated levels of serum DHEA-S is influenced by the pretreatment level.	Clomiphene	76-94	sulfotransferase family 2A member 1	Homo sapiens	142-148
4054664-0	1985	[Prolactin levels in women with polycystic ovary syndrome after treatment with clomiphene].	Clomiphene	79-89	prolactin	Homo sapiens	1-10
3919045-3	1985	Patients given human menopausal gonadotropin and clomiphene citrate had significantly higher levels of plasma PRL compared to those given clomiphene only.	Clomiphene	49-67	prolactin	Homo sapiens	110-113
3919045-3	1985	Patients given human menopausal gonadotropin and clomiphene citrate had significantly higher levels of plasma PRL compared to those given clomiphene only.	Clomiphene	49-59	prolactin	Homo sapiens	110-113
3917407-1	1985	Seventy-three treatment courses of pulsatile gonadotropin-releasing hormone (GnRH) were given to 19 patients with clomiphene nonresponsive anovulatory infertility.	Clomiphene	114-124	gonadotropin releasing hormone 1	Homo sapiens	77-81
6388205-0	1984	Hydrocortisone elicits the effect of clomiphene citrate on luteinizing hormone-releasing hormone release in vitro.	Clomiphene	37-55	gonadotropin releasing hormone 1	Rattus norvegicus	59-96
4038961-0	1985	[Estradiol, luteinizing hormone, testosterone and sex hormone-binding globulin in the clomiphene-induced menstrual cycle].	Clomiphene	86-96	sex hormone binding globulin	Homo sapiens	50-78
6695548-2	1984	The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion.	Clomiphene	151-161	prolactin	Homo sapiens	22-25
16725938-12	1984	The results suggest that clomid at this dosage inhibits GnRH-induced release of LH from the pituitary of rams but not of wethers.	Clomiphene	25-31	gonadotropin releasing hormone 1	Homo sapiens	56-60
6727539-5	1984	In animals treated with clomiphene, the inhibition by SCT on PRL increase after injection stress was partially abolished.	Clomiphene	24-34	prolactin	Homo sapiens	61-64
16725938-0	1984	Effect of clomiphene citrate on pituitary responsiveness to gonadotropin releasing hormone in rams and wethers.	Clomiphene	10-28	gonadotropin releasing hormone 1	Homo sapiens	60-90
16725938-1	1984	The objective of this study was to determine the effect of clomiphene citrate (clomid) on pituitary responsiveness to gonadotropin releasing hormone (GnRH) in rams and wethers.	Clomiphene	59-77	gonadotropin releasing hormone 1	Homo sapiens	118-148
16725938-1	1984	The objective of this study was to determine the effect of clomiphene citrate (clomid) on pituitary responsiveness to gonadotropin releasing hormone (GnRH) in rams and wethers.	Clomiphene	59-77	gonadotropin releasing hormone 1	Homo sapiens	150-154
16725938-1	1984	The objective of this study was to determine the effect of clomiphene citrate (clomid) on pituitary responsiveness to gonadotropin releasing hormone (GnRH) in rams and wethers.	Clomiphene	79-85	gonadotropin releasing hormone 1	Homo sapiens	118-148
16725938-1	1984	The objective of this study was to determine the effect of clomiphene citrate (clomid) on pituitary responsiveness to gonadotropin releasing hormone (GnRH) in rams and wethers.	Clomiphene	79-85	gonadotropin releasing hormone 1	Homo sapiens	150-154
16725938-5	1984	The second GnRH challenge was administered 0.5 hours after an injection of clomid or vehicle (4.5% sorbitol solution) which was given on the third hour.	Clomiphene	75-81	gonadotropin releasing hormone 1	Homo sapiens	11-15
16725938-6	1984	The relative response to clomid or vehicle was calculated as the mean increase in concentration of LH during the two-hour period after the second GnRH injection.	Clomiphene	25-31	gonadotropin releasing hormone 1	Homo sapiens	146-150
6376665-8	1984	The results demonstrate that the self-priming effect is more restored in the clomiphene-positive group than in the clomiphene-negative group, and the data also indicate that the analysis of the self-priming effect with the "LH-RH two step test" is useful in developing new diagnostic criteria on ovarian dysfunction.	Clomiphene	77-87	gonadotropin releasing hormone 1	Homo sapiens	224-229
6672461-5	1983	A single administration of 200 micrograms clomiphene in the estrogenized rats, on the other hand, increased nuclear ER gradually.	Clomiphene	42-52	estrogen receptor 1	Rattus norvegicus	116-118
6349205-0	1983	Clomiphene citrate induces luteinizing hormone release through hypothalamic luteinizing hormone-releasing hormone in vitro.	Clomiphene	0-18	gonadotropin releasing hormone 1	Rattus norvegicus	76-113
6354756-5	1983	The results imply normal operation of the ovarian-pituitary feedback loop and suggest that subcutaneous pulsatile GnRH therapy is a safe and effective means of ovulation induction in clomiphene-resistant cases of hypothalamic amenorrhea and may possibly become the preferred method of treatment.	Clomiphene	183-193	gonadotropin releasing hormone 1	Homo sapiens	114-118
6626264-1	1983	Estrogen receptor affinity and antiestrogenic activity of clomiphene metabolites.	Clomiphene	58-68	estrogen receptor 1	Rattus norvegicus	0-17
6626264-6	1983	The relative uterine cytosol estrogen receptor binding affinities, at 4 degrees, of 4-hydroxyclomiphene and the E-isomers of clomiphene, desethylclomiphene, and clomiphene N-oxide were, in turn, 331, 0.71, 0.62, and 0.88 (estradiol = 100).	Clomiphene	93-103	estrogen receptor 1	Rattus norvegicus	29-46
6408114-0	1983	Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site.	Clomiphene	22-32	estrogen receptor 1	Homo sapiens	84-101
6411992-5	1983	This was, presumably, an estrogenic effect since non aromatizable androgens did not increase the PRL response; moreover, the antioestrogen, clomiphene, decreased the PRL response when given with HCG.	Clomiphene	140-150	prolactin	Homo sapiens	166-169
6133787-1	1983	Luteinizing hormone-releasing hormone (LH-RH) was used to induce ovulation following clomiphene priming to stimulate follicular growth.	Clomiphene	85-95	gonadotropin releasing hormone 1	Homo sapiens	0-37
6133787-1	1983	Luteinizing hormone-releasing hormone (LH-RH) was used to induce ovulation following clomiphene priming to stimulate follicular growth.	Clomiphene	85-95	gonadotropin releasing hormone 1	Homo sapiens	39-44
6781360-1	1981	The direct effects of clomiphene citrate (Clomid), tamoxifen, and estradiol (E2) on the gonadotropin-releasing hormone (GnRH)-stimulated release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were studied in cultured anterior pituitary cells obtained from adult ovariectomized rats.	Clomiphene	22-40	gonadotropin releasing hormone 1	Rattus norvegicus	120-124
6753813-0	1982	Luteinizing hormone-releasing hormone (LH-RH) treatment for inducing clomiphene response in anovulatory patients with hypogonadotropic hypogonadism.	Clomiphene	69-79	gonadotropin releasing hormone 1	Homo sapiens	0-37
6753813-0	1982	Luteinizing hormone-releasing hormone (LH-RH) treatment for inducing clomiphene response in anovulatory patients with hypogonadotropic hypogonadism.	Clomiphene	69-79	gonadotropin releasing hormone 1	Homo sapiens	39-44
7047009-0	1982	[Plasma LH-RH secretion after administration of clomiphene citrate in hypogonadotropic hypogonadism (author"s transl)].	Clomiphene	48-66	gonadotropin releasing hormone 1	Homo sapiens	8-13
7078848-3	1982	This information was used to time midcycle human chorionic gonadotropin (hCG) administration in over 97 cycles in 21 patients responsive to clomiphene who had not conceived.	Clomiphene	140-150	chorionic gonadotropin subunit beta 5	Homo sapiens	73-76
7078848-8	1982	Timing of midcycle hCG using ultrasound is an effective method of inducing ovulation in patients in whom an estrogenic follicular response without ovulation is obtained with clomiphene treatment.	Clomiphene	174-184	chorionic gonadotropin subunit beta 5	Homo sapiens	19-22
6781360-1	1981	The direct effects of clomiphene citrate (Clomid), tamoxifen, and estradiol (E2) on the gonadotropin-releasing hormone (GnRH)-stimulated release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were studied in cultured anterior pituitary cells obtained from adult ovariectomized rats.	Clomiphene	42-48	gonadotropin releasing hormone 1	Rattus norvegicus	120-124
6781360-4	1981	Our findings suggest that Clomid and its Enclomid isomer, unlike tamoxifen, exert a direct estrogenic rather than an antiestrogenic effect on cultured pituitary cells by enhancing the GnRH-stimulated release of gonadotropin.	Clomiphene	26-32	gonadotropin releasing hormone 1	Rattus norvegicus	184-188
6122657-1	1982	Some biochemical and biophysical variables of human follicular fluid have been studied both in normal women after the LH peak (preovulatory follicles) and in women treated with clomiphene and hCG (clomiphene treated follicles).	Clomiphene	197-207	hypertrichosis 2 (generalised, congenital)	Homo sapiens	192-195
6797954-0	1981	Effect of clomiphene treatment on the human testicular response to a single dose of hCG.	Clomiphene	10-20	hypertrichosis 2 (generalised, congenital)	Homo sapiens	84-87
6797955-0	1981	The effect of clomiphene citrate on sex hormone binding globulin in normospermic and oligozoospermic men.	Clomiphene	14-32	sex hormone binding globulin	Homo sapiens	36-64
6797955-1	1981	The effect of clomiphene citrate (CG) on sex hormone binding globulin (SHBG) was studied in 10 oligozoospermic patients with varicocele and 6 normospermic men.	Clomiphene	14-32	sex hormone binding globulin	Homo sapiens	71-75
7286252-2	1981	When the results of 120 stimulated cycles were compared with those from 213 spontaneous cycles during a one-year period, the clomiphene-ultrasound-hCG method led to a significantly higher laparoscopy rate as well as significantly better yields of mature oocytes and embryos for intrauterine transfer.	Clomiphene	125-135	chorionic gonadotropin subunit beta 5	Homo sapiens	147-150
6781360-1	1981	The direct effects of clomiphene citrate (Clomid), tamoxifen, and estradiol (E2) on the gonadotropin-releasing hormone (GnRH)-stimulated release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were studied in cultured anterior pituitary cells obtained from adult ovariectomized rats.	Clomiphene	42-48	gonadotropin releasing hormone 1	Rattus norvegicus	88-118
6780589-0	1981	Clomiphene attenuates the exaggerated prolactin response to thyrotropin-releasing hormone and metoclopramide occurring in primary testicular failure.	Clomiphene	0-10	thyrotropin releasing hormone	Homo sapiens	60-89
6767631-0	1980	Effect of clomiphene citrate on corticosteroid-binding globulin and serum progesterone levels during ovulation induction.	Clomiphene	10-28	serpin family A member 6	Homo sapiens	32-63
6767631-2	1980	Significant elevations (P less than 0.05) of serum corticosteroid-binding globulin were noted in patients under therapy with Clomid.	Clomiphene	125-131	serpin family A member 6	Homo sapiens	51-82
6108933-2	1980	According to the degree of endogenous LH-RH deficiency, which is reflected by this diagnostic workup, a therapy with clomiphene alone, LH-RH combined with clomiphene, or LH-RH alone is effective.	Clomiphene	117-127	gonadotropin releasing hormone 1	Homo sapiens	38-43
6108933-2	1980	According to the degree of endogenous LH-RH deficiency, which is reflected by this diagnostic workup, a therapy with clomiphene alone, LH-RH combined with clomiphene, or LH-RH alone is effective.	Clomiphene	155-165	gonadotropin releasing hormone 1	Homo sapiens	38-43
6108933-4	1980	Thus pulsatile and low-dose LH-RH administration of varied duration proved able to prime the hypothalamo-pituitary unit for either clomiphene or gonadal feedback signals resulting in ovulation and corpus luteum formation.	Clomiphene	131-141	gonadotropin releasing hormone 1	Homo sapiens	28-33
363308-0	1978	Oestrogen amplification of LH-RH response in the polycystic ovary syndrome and response to clomiphene.	Clomiphene	91-101	gonadotropin releasing hormone 1	Homo sapiens	27-32
377969-3	1979	Following dexamethasone administration, the LH and FSH response to clomiphene citrate, which competes for gonadal steroid receptor binding sites in the hypothalamus, resulting in increased release of LHRH, was blunted in the 10 women studied.	Clomiphene	67-85	gonadotropin releasing hormone 1	Homo sapiens	200-204
420416-0	1979	Histochemical studies of testicular delta5-3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase after chronic indomethacin administration in rats pretreated with clomiphene-citrate.	Clomiphene	184-202	aldo-keto reductase family 1, member C12	Rattus norvegicus	82-117
420416-1	1979	Histochemical studies of testicular delta5-3beta-Hydroxysteroid Dehydrogenase and 17beta-Hydroxysteroid Dehydrogenase in sexually immature rats treated chronically with simultaneous Indomethacin and Clomiphene revealed greater inhibition in the enzyme activities when compared to Clomiphene treated animals alone.	Clomiphene	199-209	aldo-keto reductase family 1, member C12	Rattus norvegicus	82-117
760769-1	1979	Clomiphene was administered to 16 patients with elevated serum prolactin levels in doses of 100, 200 and 300 mg/day for five days in succeeding months and total urinary oestrogens estimated on days 0, 5, 8, 12 and 15 following commencement of treatment.	Clomiphene	0-10	prolactin	Homo sapiens	63-72
398374-2	1979	Five different types of response, similar to those detected in previous studies using the LH-RH test, are identified; in them, uniformity in the response of gonadotropins exists to both LH-RH and Clomifene.	Clomiphene	196-205	gonadotropin releasing hormone 1	Homo sapiens	90-95
210670-0	1978	Prenatal detection of a familial t(1;7)(p32;p13) translocation transmitted in a pregnancy occurring after administration of clomiphene and conjugated estrogens.	Clomiphene	124-134	inhibitor of growth family member 2	Homo sapiens	40-43
210670-0	1978	Prenatal detection of a familial t(1;7)(p32;p13) translocation transmitted in a pregnancy occurring after administration of clomiphene and conjugated estrogens.	Clomiphene	124-134	H3 histone pseudogene 6	Homo sapiens	44-47
348501-2	1978	A daily 100-mg dose of clomiphene citrate induced a marked, significant increase in plasma immunoreactive LH-RH levels, followed by significant increments in gonadotropin and testosterone values.	Clomiphene	23-41	gonadotropin releasing hormone 1	Homo sapiens	106-111
336077-0	1977	Effect of clomiphene on prolactin secretion and lactation in puerperal women.	Clomiphene	10-20	prolactin	Homo sapiens	24-33
663870-0	1978	Ovulation induction stimulated with HCG in functional sterility patients treated with clomiphene.	Clomiphene	86-96	hypertrichosis 2 (generalised, congenital)	Homo sapiens	36-39
789117-0	1976	The relationship between the pituitary response to luteinizing hormone-releasing hormone and the ovulatory response to clomiphene citrate.	Clomiphene	119-137	gonadotropin releasing hormone 1	Homo sapiens	51-88
320225-2	1977	Premedication of clomiphene citrate depresses peak values of LH and FSH on LH-RH in delayed puberty.	Clomiphene	17-35	gonadotropin releasing hormone 1	Homo sapiens	75-80
320225-3	1977	In hypogonadotropic hypogonadism clomiphene citrate raises LH-RH induced peak LH while FSH does not change.	Clomiphene	33-51	gonadotropin releasing hormone 1	Homo sapiens	59-64
20414-7	1977	Gonadotropin treatment was successful in 20 patients, clomiphene-hCG in two, tamoxifen in two, bromocriptine in two, and combined bromocriptine and clomiphene in one.	Clomiphene	54-64	hypertrichosis 2 (generalised, congenital)	Homo sapiens	65-68
925574-0	1977	Effect of clomiphene on release of prolactin induced by mechanical breast emptying in women post partum.	Clomiphene	10-20	prolactin	Homo sapiens	35-44
872951-3	1977	It is concluded that clomiphene may aid in confirming the diagnosis and establishing a prognosis in patients with primary or secondary amenorrhea.	Clomiphene	21-31	activation induced cytidine deaminase	Homo sapiens	36-39
557719-6	1977	Serum PRL levels were of value in predicting the likely success in achieving ovulation with clomiphene citrate or CB-154; clomiphene citrate was less likely to be successful in the presence of hyperprolactinaemia, whereas the reverse applied for treatment with CB-154.	Clomiphene	92-110	prolactin	Homo sapiens	6-9
789117-6	1976	Of the 11 patients in the group with secondary amenorrhea who had a "positive" response to LH-RH, 7 ovulated at a dose of 150 mg (or less) of clomiphene citrate, while only 1 of the 11 patients with a "negative" response ovulated while receiving a similar dosage of clomiphene.	Clomiphene	142-160	gonadotropin releasing hormone 1	Homo sapiens	91-96
824160-5	1976	FSH/LH-RH can be utilized for supplementing the LH surge after clomiphene therapy in cases of clomiphene failure.	Clomiphene	63-73	gonadotropin releasing hormone 1	Homo sapiens	4-9
780364-7	1976	The small dose (10 mug x 5) of pulses of LRF was utilized in the assessment of estrogen and clomiphene treatments on the functional capacity of the gonadotrophs in normal men.	Clomiphene	92-102	CREB3 regulatory factor	Homo sapiens	41-44
780364-9	1976	Clomiphene treatment (100 mg/day x 5 d), likewise, resulted in a reduction of gonadotropin release to all pulses of LRF.	Clomiphene	0-10	CREB3 regulatory factor	Homo sapiens	116-119
1099113-6	1975	The LY and FSH responses to LH-RH administration was greater after 6 weeks of clomiphene citrate therapy than they were either before (both patients) or 6 months after treatment (1 patient).	Clomiphene	78-96	gonadotropin releasing hormone 1	Homo sapiens	28-33
782129-0	1976	[The LHRH test for measuring the pituitary gonadotropin reserve in patients pretreated with clomiphene].	Clomiphene	92-102	gonadotropin releasing hormone 1	Homo sapiens	5-9
785926-5	1976	On the other hand, a negative response to the injection of 100 mug LH-RH does not necessarily imply a pituitary lesion but is often a sign of altered hypothalamic function which can be diagnosed and in some instances restored by clomiphene administration.	Clomiphene	229-239	gonadotropin releasing hormone 1	Homo sapiens	67-72
177345-4	1976	It is concluded from these results that clomiphene unlike most other antilipolytic drugs exerts its antilipolytic effect by an inhibition of the lipase rather than by inhibition of adenylcyclase.	Clomiphene	40-50	lipase G, endothelial type	Rattus norvegicus	145-151
1107347-0	1975	LH and FSH response to synthetic LHRH after consecutive administration of clomiphene citrate in normal males.	Clomiphene	74-92	gonadotropin releasing hormone 1	Homo sapiens	33-37
1107347-2	1975	Serum FSH, both pre and post LHRH levels (peak value and area under response curve) were significantly increased (P less than 0.01) by clomiphene citrate, while the maximum increments of FSH above baseline (deltaFSH) and area under response curve from basal level (deltaarea) were unchanged.	Clomiphene	135-153	gonadotropin releasing hormone 1	Homo sapiens	29-33
1102554-7	1975	These results suggest that long-term treatment with synthetic LHRH may be effective for gonadotropin restoration in some patients with hypothalamic hypogonadism in which long-term treatment of clomiphene citrate was shown to be ineffective.	Clomiphene	193-211	gonadotropin releasing hormone 1	Homo sapiens	62-66
773574-7	1976	The decreased gonadotrophin response to LHRH during clomiphene treatment is thought to be caused by a relative and temporary pituitary depletion of the releasable gonadotrophin content.	Clomiphene	52-62	gonadotropin releasing hormone 1	Homo sapiens	40-44
1247048-0	1976	Effect of clomiphene citrate on serum prolactin in infertile women with ovarian dysfunction.	Clomiphene	10-28	prolactin	Homo sapiens	38-47
1247048-8	1976	The serum PRL levels were normal during the control cycle in five of the patients who ovulated with Clomid and high in four patients who failed to ovulate.	Clomiphene	100-106	prolactin	Homo sapiens	10-13
1247048-9	1976	Although serum PRL levels were not significantly changed by Clomid in the patients who ovulated with the drug, they were markedly decreased during and immediately after Clomid treatment in patients who failed to ovulate with Clomid.	Clomiphene	169-175	prolactin	Homo sapiens	15-18
1247048-9	1976	Although serum PRL levels were not significantly changed by Clomid in the patients who ovulated with the drug, they were markedly decreased during and immediately after Clomid treatment in patients who failed to ovulate with Clomid.	Clomiphene	169-175	prolactin	Homo sapiens	15-18
992480-2	1976	Cis-clomiphene produced UBF increases comparable to or greater than those produced by estradiol-17beta but at dose levels 20 times greater.	Clomiphene	0-14	upstream binding transcription factor	Homo sapiens	24-27
992480-3	1976	Comparison of UBF response curves for cis-clomiphene with those for estradiol-17beta showed a delayed onset of initial vasodilation and a delayed peak response.	Clomiphene	38-52	upstream binding transcription factor	Homo sapiens	14-17
992480-6	1976	The characteristics of clomiphene-induced UBF responses that differed from those after estradiol-17beta may reflect differences in estrogen receptor activation between the compounds.	Clomiphene	23-33	upstream binding transcription factor	Homo sapiens	42-45
1098942-2	1975	LH-RH was administered 6 days after clomiphene to 18 amenorrheic, anovulatory, infertile women in whom clomiphene therapy had failed previously.	Clomiphene	103-113	gonadotropin releasing hormone 1	Homo sapiens	0-5
1099113-8	1975	A normal adult response of gonadotropins to the administration of LH-RH was acheived during clomiphene citrate therapy.	Clomiphene	92-110	gonadotropin releasing hormone 1	Homo sapiens	66-71
1092124-0	1975	[Sequential clomiphene-LH-RH test in amenorrhea and anovulatory amenorrhea].	Clomiphene	12-22	gonadotropin releasing hormone 1	Homo sapiens	23-28
1097463-3	1975	However, the pituitary release of LH and FSH in response to LRF was markedly diminished by the clomiphene treatment.	Clomiphene	95-105	CREB3 regulatory factor	Homo sapiens	60-63
4388641-0	1969	Effect of cis and trans isomers of clomiphene citrate on uterine hexokinase activity.	Clomiphene	35-53	hexokinase 1	Homo sapiens	65-75
233937-4	1975	The anti-estrogenic agent clomiphene was found to effectively antagonize the formation of cyclic AMP elicited by E2 and DES, while having no stimulatory effects  on cyclic AMP formation itself.	Clomiphene	26-36	dihydrolipoamide S-succinyltransferase	Rattus norvegicus	113-123
4375270-0	1974	In vivo blockade of the estradiol-binding-protein (EBP) by clomiphene citrate in human breast cancer.	Clomiphene	59-77	EBP cholestenol delta-isomerase	Homo sapiens	24-49
4375270-0	1974	In vivo blockade of the estradiol-binding-protein (EBP) by clomiphene citrate in human breast cancer.	Clomiphene	59-77	EBP cholestenol delta-isomerase	Homo sapiens	51-54
4375271-0	1974	In vivo blockade of the estradiol-binding-protein (EBP) by clomiphene citrate in human breast cancer.	Clomiphene	59-77	EBP cholestenol delta-isomerase	Homo sapiens	24-49
4375271-0	1974	In vivo blockade of the estradiol-binding-protein (EBP) by clomiphene citrate in human breast cancer.	Clomiphene	59-77	EBP cholestenol delta-isomerase	Homo sapiens	51-54
4784616-2	1973	Metabolism of progesterone during esterase inhibition with clomiphene citrate.	Clomiphene	59-77	esterase	Purpureocillium lilacinum	34-42
1088908-1	1975	To delineate the role of estradiol in the augmented pituitary gonadotropin responsiveness to synthetic luteinizing hormone releasing factor (LRF) seen during high-estrogen phases of the ovulatory cycles (late follicular and midluteal phases), the anti-estrogenic effect of clomiphene citrate (Clomid) on pituitary response to LRF was evaluated during different phases of the ovulatory cycle.	Clomiphene	273-291	CREB3 regulatory factor	Homo sapiens	141-144
1088908-1	1975	To delineate the role of estradiol in the augmented pituitary gonadotropin responsiveness to synthetic luteinizing hormone releasing factor (LRF) seen during high-estrogen phases of the ovulatory cycles (late follicular and midluteal phases), the anti-estrogenic effect of clomiphene citrate (Clomid) on pituitary response to LRF was evaluated during different phases of the ovulatory cycle.	Clomiphene	293-299	CREB3 regulatory factor	Homo sapiens	141-144
1088908-2	1975	Clomid administration (100 mg/day times 5 days) completely negates the augmented gonadotropin responses to LRF (150 mug) during late follicular and midluteal phases observed during the control studies.	Clomiphene	0-6	CREB3 regulatory factor	Homo sapiens	107-110
1088908-3	1975	Thus, a quantitatively and qualitatively similar pituitary sensitivity to LRF during three distinct phases of the menstrual cycle was induced by Clomid treatment that resembles the LRF responsiveness of themale pituitary.	Clomiphene	145-151	CREB3 regulatory factor	Homo sapiens	74-77
4795232-0	1973	Reduction of growth hormone secretion following clomiphene administration.	Clomiphene	48-58	growth hormone 1	Homo sapiens	13-27
4921650-0	1970	Increased release of LH after administration of LH-RH to men pretreated with clomiphene.	Clomiphene	77-87	gonadotropin releasing hormone 1	Homo sapiens	48-53
4895859-0	1969	Arginine induced growth hormone release after clomiphene treatment.	Clomiphene	46-56	growth hormone 1	Homo sapiens	17-31
32799715-0	2021	Does ischaemia-modified albumin level predict clomiphene citrate resistant polycystic ovary syndrome patients?	Clomiphene	46-64	albumin	Homo sapiens	24-31
33934267-1	2021	PURPOSE: To assess whether anti-Mullerian hormone (AMH) can predict response to ovulation induction (OI) with clomiphene citrate (CC), letrozole (LET), or follicle-stimulating hormone (FSH) in women with polycystic ovary syndrome (PCOS) undergoing OI/intrauterine inseminations (IUI).	Clomiphene	110-128	anti-Mullerian hormone	Homo sapiens	27-49
33934267-1	2021	PURPOSE: To assess whether anti-Mullerian hormone (AMH) can predict response to ovulation induction (OI) with clomiphene citrate (CC), letrozole (LET), or follicle-stimulating hormone (FSH) in women with polycystic ovary syndrome (PCOS) undergoing OI/intrauterine inseminations (IUI).	Clomiphene	110-128	anti-Mullerian hormone	Homo sapiens	51-54
32799715-1	2021	This study aims to examine the role of ischaemic-modified albumin (IMA) in predicting clomiphene citrate (CC) resistance in patients with CC-resistant and CC-sensitive infertile polycystic ovary syndrome (PCOS).	Clomiphene	86-104	albumin	Homo sapiens	58-65
32502769-11	2020	Furthermore, by employing open-source, biological data we identified a common gene (Estrogen Receptor 1, ESR1) between genetic targets of clomiphene treatment and POR which could explain the benefits of clomiphene in this group of patients.	Clomiphene	138-148	estrogen receptor 1	Homo sapiens	84-103
33246461-2	2020	In this study, we aimed to analyze the correlation of the serum AMH level with ovarian responsiveness, embryonic outcomes, and cumulative live birth rates in clomiphene citrate (CC)-based minimal ovarian stimulation cycles.	Clomiphene	158-176	anti-Mullerian hormone	Homo sapiens	64-67
33841532-0	2020	Comparison the Effect of Metformin and Clomiphene Citrate on Sirtuin3 gene Expression in the Oocytes of Mice with Polycystic Ovary Syndrome.	Clomiphene	39-57	sirtuin 3	Mus musculus	61-69
33841532-3	2020	In the current study, we compared the effects of metformin and clomiphene citrate on the expression of the Sirt3 gene in oocytes obtained from the mice, induced by PCOS.	Clomiphene	63-81	sirtuin 3	Mus musculus	107-112
33841532-12	2020	The administration of metformin and clomiphene showed that metformin is capable of preventing the downregulation of the Sirt3 gene in oocytes, collected from PCOS mice.	Clomiphene	36-46	sirtuin 3	Mus musculus	120-125
32131660-4	2021	Ferroxidase, catalase and myeloperoxidase levels were determined to be lower in the clomiphene citrate-resistant group compared to clomiphene citrate-sensitive and non-polycystic ovary syndrome groups (p < .001).	Clomiphene	84-102	myeloperoxidase	Homo sapiens	26-41
32131660-5	2021	As a result, Polycystic ovary syndrome patients with clomiphene resistance had lower antioxidant (catalase and ferroxidase) levels compared to those who were sensitive to clomiphene and who did not have polycystic ovary syndrome.	Clomiphene	53-63	catalase	Homo sapiens	98-106
32131660-9	2021	In this study, the antioxidants catalase and ferroxidase were found to be lower in PCOS women compared to non-PCOS; however, they were the lowest in clomiphene citrate-resistant PCOS women.	Clomiphene	149-167	catalase	Homo sapiens	32-40
32502769-11	2020	Furthermore, by employing open-source, biological data we identified a common gene (Estrogen Receptor 1, ESR1) between genetic targets of clomiphene treatment and POR which could explain the benefits of clomiphene in this group of patients.	Clomiphene	138-148	estrogen receptor 1	Homo sapiens	105-109
32502769-11	2020	Furthermore, by employing open-source, biological data we identified a common gene (Estrogen Receptor 1, ESR1) between genetic targets of clomiphene treatment and POR which could explain the benefits of clomiphene in this group of patients.	Clomiphene	203-213	estrogen receptor 1	Homo sapiens	84-103
32502769-11	2020	Furthermore, by employing open-source, biological data we identified a common gene (Estrogen Receptor 1, ESR1) between genetic targets of clomiphene treatment and POR which could explain the benefits of clomiphene in this group of patients.	Clomiphene	203-213	estrogen receptor 1	Homo sapiens	105-109
32528768-2	2020	Anti-Mullerian hormone (AMH) not only reflects the ovarian reserve but also is known to be a predictor of several assisted reproductive techniques, e.g., in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and clomiphene citrate challenge test.	Clomiphene	229-247	anti-Mullerian hormone	Homo sapiens	24-27
32528768-3	2020	In this study, AMH levels are correlated with the follicular output rate after the clomiphene citrate challenge test.	Clomiphene	83-101	anti-Mullerian hormone	Homo sapiens	15-18
32528768-4	2020	Objective The objective of this study is to correlate AMH with the follicular output rate (FORT) after the clomiphene citrate challenge test.	Clomiphene	107-125	anti-Mullerian hormone	Homo sapiens	54-57
32528768-10	2020	Conclusion It is concluded that the most commonly administered drug, clomiphene citrate, may not be the treatment of choice for patients with high levels of AMH and may, in fact, interfere with the chances of achieving pregnancy.	Clomiphene	69-87	anti-Mullerian hormone	Homo sapiens	157-160
32528768-11	2020	This study can provide guidelines to clinicians for patient counseling, given the results of the clomiphene citrate challenge test on the basis of AMH levels.	Clomiphene	97-115	anti-Mullerian hormone	Homo sapiens	147-150
32197603-3	2020	Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 and tozasertib to their corresponding N-oxide metabolites.	Clomiphene	165-175	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	83-87
32197603-3	2020	Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 and tozasertib to their corresponding N-oxide metabolites.	Clomiphene	165-175	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	89-130
31475495-3	2019	On the 1st cycle of IVF-ET, these POR women received microstimulation of ovulation program (oral administration of Clomiphene, muscular injection of Menotrophin, Chorionic Gonadotrophin triggering, etc.).	Clomiphene	115-125	cytochrome p450 oxidoreductase	Homo sapiens	34-37
32046414-1	2020	The study was designed to investigate whether laparoscopic ovarian drilling (LOD) of ovaries alters the expression levels of HOXA-10 and HOXA-11 mRNA in the endometrium of infertile women with clomiphene-resistant PCOS.	Clomiphene	193-203	homeobox A10	Homo sapiens	125-132
32046414-1	2020	The study was designed to investigate whether laparoscopic ovarian drilling (LOD) of ovaries alters the expression levels of HOXA-10 and HOXA-11 mRNA in the endometrium of infertile women with clomiphene-resistant PCOS.	Clomiphene	193-203	homeobox A11	Homo sapiens	137-144
31401157-0	2019	Clomiphene promotes browning of white adipocytes via casein kinase-2 inhibition.	Clomiphene	0-10	casein kinase 2, alpha prime polypeptide	Mus musculus	53-68
31401157-4	2019	Clomiphene was found to inhibit CK2 activity with an IC50 of 2.39 muM.	Clomiphene	0-10	casein kinase 2, alpha prime polypeptide	Mus musculus	32-35
31401157-5	2019	Accordingly, clomiphene increased mRNA and protein expression of browning markers, including uncoupling protein-1 (UCP1) in 3T3-L1 white adipocytes and in murine primary adipocytes.	Clomiphene	13-23	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	93-119
31401157-7	2019	Furthermore, phosphorylation of histone deacetylase (HDAC) 1 and 2, downstream mediators of CK2 actions, was decreased by clomiphene.	Clomiphene	122-132	histone deacetylase 1	Mus musculus	32-66
31401157-7	2019	Furthermore, phosphorylation of histone deacetylase (HDAC) 1 and 2, downstream mediators of CK2 actions, was decreased by clomiphene.	Clomiphene	122-132	casein kinase 2, alpha prime polypeptide	Mus musculus	92-95
31401157-8	2019	On the other hand, CK2 overexpression diminished clomiphene-induced mitochondrial biogenesis as well as expression of browning markers, suggesting that clomiphene-induced browning is related to its inhibition of CK2.	Clomiphene	49-59	casein kinase 2, alpha prime polypeptide	Mus musculus	19-22
31401157-8	2019	On the other hand, CK2 overexpression diminished clomiphene-induced mitochondrial biogenesis as well as expression of browning markers, suggesting that clomiphene-induced browning is related to its inhibition of CK2.	Clomiphene	152-162	casein kinase 2, alpha prime polypeptide	Mus musculus	19-22
31401157-8	2019	On the other hand, CK2 overexpression diminished clomiphene-induced mitochondrial biogenesis as well as expression of browning markers, suggesting that clomiphene-induced browning is related to its inhibition of CK2.	Clomiphene	152-162	casein kinase 2, alpha prime polypeptide	Mus musculus	212-215
31401157-10	2019	In summary, these data suggested that clomiphene induced the browning of white adipocytes via CK2 inhibition, which may implicate it as a new anti-obesity drug.	Clomiphene	38-48	casein kinase 2, alpha prime polypeptide	Mus musculus	94-97
31618328-8	2019	SREBP1 expression was inhibited after treatment, while the inhibitory effects of combined treatment were stronger than those of clomifene citrate alone.	Clomiphene	128-145	sterol regulatory element binding transcription factor 1	Homo sapiens	0-6
31041823-0	2019	The effect of clomiphene citrate and human chorionic gonadotropin on the expression of CatSper1, CatSper2, LHCGR, and SF1 genes, as well as the structural changes in testicular tissue of adult rats.	Clomiphene	14-32	cation channel sperm associated 1	Homo sapiens	87-95
31508563-0	2019	Clomiphene citrate impairs the endometrial CD98 expression in ovariectomized and non-ovariectomized rats: Role of HCG.	Clomiphene	0-18	solute carrier family 3 member 2	Homo sapiens	43-47
31423417-12	2019	Fasting insulin was the best metabolic predictor of the non-responsiveness to clomiphene.	Clomiphene	78-88	insulin	Homo sapiens	8-15
31041823-9	2019	According to the obtained results, it seems that clomiphene citrate reduces the process of spermatogenesis and the detrimental impacts of this compound would be neutralized by the administration of HCG.	Clomiphene	49-67	chorionic gonadotropin subunit beta 5	Homo sapiens	198-201
30471247-0	2019	Clomiphene citrate induces nuclear translocation of the TFEB transcription factor and triggers apoptosis by enhancing lysosomal membrane permeabilization.	Clomiphene	0-18	transcription factor EB	Homo sapiens	56-60
30471247-4	2019	Here, we describe that clomiphene citrate (CC), a selective estrogen receptor modulator, promotes nuclear translocation of TFEB and increases lysosomal biogenesis in HeLa and MDA-MB-231 cells.	Clomiphene	23-41	transcription factor EB	Homo sapiens	123-127
29959872-0	2018	Flavin-Containing Monooxygenase 3 Polymorphic Variants Significantly Affect Clearance of Tamoxifen and Clomiphene.	Clomiphene	103-113	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	0-33
30044165-0	2019	The role of anti-Mullerian hormone in predicting clomiphene citrate resistance in women with polycystic ovarian syndrome.	Clomiphene	49-67	anti-Mullerian hormone	Homo sapiens	12-34
29959872-3	2018	The purpose of this study was to investigate the effect of the three common polymorphic variants of hFMO3 (V257M, E158K and E308G) on the metabolism and clearance of three structurally similar compounds: tamoxifen (breast cancer medication), clomiphene (infertility medication) and GSK5182 (antidiabetic lead molecule).	Clomiphene	242-252	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	100-105
30342657-0	2018	The role of anti-Mullerian hormone in predicting the response to clomiphene citrate in unexplained infertility.	Clomiphene	65-83	anti-Mullerian hormone	Homo sapiens	12-34
30141889-10	2018	In conclusion, the resistance to clomiphene manifested by the patient might be explained by a potential mechanism implicating inhibin B and AMH due to the presence of a GCT.	Clomiphene	33-43	anti-Mullerian hormone	Homo sapiens	140-143
30342657-1	2018	OBJECTIVE: To determine the role of anti-Mullerian hormone (AMH) levels in predicting the response to clomiphene citrate (CC) therapy for ovulation induction in women with unexplained infertility.	Clomiphene	102-120	anti-Mullerian hormone	Homo sapiens	36-58
30342657-1	2018	OBJECTIVE: To determine the role of anti-Mullerian hormone (AMH) levels in predicting the response to clomiphene citrate (CC) therapy for ovulation induction in women with unexplained infertility.	Clomiphene	102-120	anti-Mullerian hormone	Homo sapiens	60-63
29854512-3	2018	The patient received clomiphene for ovarian induction and had rising levels of human chorionic gonadotropin (hCG) over nine months without sign of pregnancy.	Clomiphene	21-31	chorionic gonadotropin subunit beta 5	Homo sapiens	85-113
29908374-0	2018	Clomiphene citrate increases nitric oxide, interleukin-10 and reduces matrix metalloproteinase-9 in women with polycystic ovary syndrome.	Clomiphene	0-18	interleukin 10	Homo sapiens	43-57
29908374-0	2018	Clomiphene citrate increases nitric oxide, interleukin-10 and reduces matrix metalloproteinase-9 in women with polycystic ovary syndrome.	Clomiphene	0-18	matrix metallopeptidase 9	Homo sapiens	70-96
29955952-0	2018	Efficacy of GnRH agonist trigger in women having history of follicular-endometrial asynchrony with clomiphene/IUI cycles in unexplained infertility.	Clomiphene	99-109	gonadotropin releasing hormone 1	Homo sapiens	12-16
29955952-2	2018	This study aims to compare the efficacy of GnRH-a with hCG in women with history of follicular-endometrial asynchrony after clomiphene in IUI cycles.	Clomiphene	124-134	gonadotropin releasing hormone 1	Homo sapiens	43-47
29955952-10	2018	CONCLUSION: In unexplained infertility, GnRH agonist is an useful alternative for triggering ovulation in women with follicular-endometrial asynchrony following clomiphene induction.	Clomiphene	161-171	gonadotropin releasing hormone 1	Homo sapiens	40-44
29908374-3	2018	The present study was done to assess the effect of clomiphene citrate on matrix metalloproteinase-9, nitric oxide and interleukin-10 levels in women with PCOS.	Clomiphene	51-69	matrix metallopeptidase 9	Homo sapiens	73-99
29908374-6	2018	RESULTS: Clomiphene citrate increases both nitric oxide (p = 0.03) and interleukin-10 (p &lt; 0.001) levels and reduces matrix metalloproteinase-9 levels (p &lt; 0.001) in women with PCOS.	Clomiphene	9-27	interleukin 10	Homo sapiens	71-85
29908374-6	2018	RESULTS: Clomiphene citrate increases both nitric oxide (p = 0.03) and interleukin-10 (p &lt; 0.001) levels and reduces matrix metalloproteinase-9 levels (p &lt; 0.001) in women with PCOS.	Clomiphene	9-27	matrix metallopeptidase 9	Homo sapiens	120-146
29908374-10	2018	CONCLUSION: We conclude that clomiphene citrate increases the levels of nitric oxide and interleukin-10 and decreases the matrix metalloproteinase - 9 levels and improves the ovulation rate and clinical pregnancy rate in PCOS.	Clomiphene	29-47	interleukin 10	Homo sapiens	89-103
29908374-10	2018	CONCLUSION: We conclude that clomiphene citrate increases the levels of nitric oxide and interleukin-10 and decreases the matrix metalloproteinase - 9 levels and improves the ovulation rate and clinical pregnancy rate in PCOS.	Clomiphene	29-47	matrix metallopeptidase 9	Homo sapiens	122-150
29510649-0	2018	The effects of letrozole and clomiphene citrate on ligands expression of Wnt3, Wnt7a, and Wnt8b in proliferative endometrium of women with Polycystic ovarian syndrome.	Clomiphene	29-47	Wnt family member 3	Homo sapiens	73-77
29510649-0	2018	The effects of letrozole and clomiphene citrate on ligands expression of Wnt3, Wnt7a, and Wnt8b in proliferative endometrium of women with Polycystic ovarian syndrome.	Clomiphene	29-47	Wnt family member 7A	Homo sapiens	79-84
29510649-0	2018	The effects of letrozole and clomiphene citrate on ligands expression of Wnt3, Wnt7a, and Wnt8b in proliferative endometrium of women with Polycystic ovarian syndrome.	Clomiphene	29-47	Wnt family member 8B	Homo sapiens	90-95
29150839-7	2018	The levels of AST and ALT returned to normal range after discontinuation of clomiphene citrate and symptomatic treatment.	Clomiphene	76-94	solute carrier family 17 member 5	Homo sapiens	14-17
30158811-0	2018	Comparison of Two Regimens of Gonadotropin-releasing Hormone Antagonists in Clomiphene-gonadotropin Induced Controlled Ovulation and Intrauterine Insemination Cycles: Randomized Controlled Study.	Clomiphene	76-86	gonadotropin releasing hormone 1	Homo sapiens	30-60
30158811-2	2018	Aims: The aim of this study is to evaluate the effectiveness of GnRH antagonists in fixed and flexible regimens on the rate of premature luteinization (PL) and ovulation rate in sequential clomiphene-gonadotropin controlled ovulation-IUI cycles.	Clomiphene	189-199	gonadotropin releasing hormone 1	Homo sapiens	64-68
29516347-0	2018	Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites.	Clomiphene	58-68	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-20
29516347-1	2018	Clomiphene citrate, a selective estrogen receptor modulator, is metabolized into its 4-hydroxylated active metabolites, primarily by CYP2D6.	Clomiphene	0-18	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	133-139
29516347-2	2018	In this study, we investigated the effects of the most common CYP2D6 variant allele in Asians, CYP2D6*10, on the pharmacokinetics of clomiphene and its two active metabolites (4-OH-CLO and 4-OH-DE-CLO) in healthy Korean subjects.	Clomiphene	133-143	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	62-68
29516347-2	2018	In this study, we investigated the effects of the most common CYP2D6 variant allele in Asians, CYP2D6*10, on the pharmacokinetics of clomiphene and its two active metabolites (4-OH-CLO and 4-OH-DE-CLO) in healthy Korean subjects.	Clomiphene	133-143	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	95-101
29516347-5	2018	There was a significant difference only in the Cmax of clomiphene between three CYP2D6 genotype groups (p &lt; 0.05).	Clomiphene	55-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	80-86
29516347-7	2018	The AUCinf of corrected clomiphene active moiety in CYP2D6*10/*10 subjects was 2.95- and 2.05-fold higher than that of CYP2D6*wt/*wt and *wt/*10 genotype groups, respectively (both p &lt; 0.001).	Clomiphene	24-34	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	52-58
29516347-8	2018	Along with the partial impacts on the biotransformation of clomiphene and its metabolites by CYP2D6 genetic polymorphism, further studies on the effects of other CYP enzymes in a multiple-dosing condition can provide more definite evidence for the inter-individual variabilities in clomiphene pharmacokinetics and/or drug response.	Clomiphene	59-69	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	93-99
29235035-3	2017	On June 27, 2017 a paper titled "Effect of acupuncture and clomiphene in Chinese women with polycystic ovary syndrome: a randomized clinical trial" was published in Journal of the American Medical Association (JAMA).	Clomiphene	59-69	F11 receptor	Homo sapiens	210-214
29408743-0	2018	Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease.	Clomiphene	157-175	tumor necrosis factor	Homo sapiens	0-27
29408743-2	2018	The aim of this work was to investigate the role of the serum level of tumor necrosis factor alpha (TNF-alpha) and other polycystic ovarian disease (PCOD) relevant clinical and biochemical factors as a predictor of spontaneous ovulation after laparoscopic ovarian drilling (LOD) in women with clomiphene citrate resistant polycystic ovarian disease (CCR-PCOD).	Clomiphene	293-311	tumor necrosis factor	Homo sapiens	71-98
29355003-0	2017	[Some issues from Effect of acupuncture and clomiphene in Chinese women with polycystic ovary syndrome in JAMA].	Clomiphene	44-54	F11 receptor	Homo sapiens	106-110
28480767-0	2017	Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate-resistant polycystic ovary disease.	Clomiphene	83-101	tumor necrosis factor	Homo sapiens	14-41
29354965-2	2017	In "Effect of acupuncture and clomiphene in Chinese women with polycystic ovary syndrome: a randomized clinical trial" published in Journal of the American Medical Association (JAMA) on June 27, 2017, the finding of this research does not support acupuncture for such infertility women.	Clomiphene	30-40	F11 receptor	Homo sapiens	177-181
28480767-1	2017	OBJECTIVE: The aim of this work was to investigate the level of the serum level of tumor necrosis factor alpha (TNF-alpha) as an inflammatory biomarker in lean and obese women with polycystic ovary disease (PCOD), who are resistant to clomiphene citrate (CCR-PCOD).	Clomiphene	235-253	tumor necrosis factor	Homo sapiens	83-110
28480767-1	2017	OBJECTIVE: The aim of this work was to investigate the level of the serum level of tumor necrosis factor alpha (TNF-alpha) as an inflammatory biomarker in lean and obese women with polycystic ovary disease (PCOD), who are resistant to clomiphene citrate (CCR-PCOD).	Clomiphene	235-253	tumor necrosis factor	Homo sapiens	112-121
28480767-6	2017	The level of TNF-alpha has come highest in the obese clomiphene citrate-resistant PCOD women (obese CCR-PCOD), while the lowest has come in the lean PCOD women, who are not resistant to clomiphene citrate (NCCR-PCOD).	Clomiphene	53-71	tumor necrosis factor	Homo sapiens	13-22
28480767-6	2017	The level of TNF-alpha has come highest in the obese clomiphene citrate-resistant PCOD women (obese CCR-PCOD), while the lowest has come in the lean PCOD women, who are not resistant to clomiphene citrate (NCCR-PCOD).	Clomiphene	186-204	tumor necrosis factor	Homo sapiens	13-22
28817891-0	2017	Re: Characterising the Safety of Clomiphene Citrate in Male Patients through Prostate-Specific Antigen, Haematocrit, and Testosterone Levels.	Clomiphene	33-51	kallikrein related peptidase 3	Homo sapiens	77-102
28826039-0	2017	Can serum vaspin levels predict clomiphene resistance in infertile women with PCOS?	Clomiphene	32-42	serpin family A member 12	Homo sapiens	10-16
28826039-1	2017	OBJECTIVE: To determine whether serum vaspin levels can predict the success of ovulation induction and clomiphene resistance in anovulatory women with PCOS.	Clomiphene	103-113	serpin family A member 12	Homo sapiens	38-44
28826039-13	2017	CONCLUSION(S): Serum vaspin level may be a useful marker for the prediction of ovulation induction success in treatment with clomiphene citrate, and increased vaspin levels (&gt;=3.74ng/mL) are correlated with clomiphene resistance in patients with PCOS according to our study results.	Clomiphene	125-143	serpin family A member 12	Homo sapiens	21-27
28826039-13	2017	CONCLUSION(S): Serum vaspin level may be a useful marker for the prediction of ovulation induction success in treatment with clomiphene citrate, and increased vaspin levels (&gt;=3.74ng/mL) are correlated with clomiphene resistance in patients with PCOS according to our study results.	Clomiphene	125-135	serpin family A member 12	Homo sapiens	21-27
29259467-8	2017	Conclusion: Clomiphene-metformin combination treatment appears to be useful, at least for clomiphene-resistant patients, and a BMI of &gt;30 kg/m2 and a fasting insulin of &gt;=15 muU/mL appear to be predictors of a good result with this treatment.	Clomiphene	12-22	insulin	Homo sapiens	161-168
28498812-0	2017	Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1.	Clomiphene	29-38	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	89-93
28498812-3	2017	The molecular docking indicated that clomifene occupied the allosteric site of the mutant IDH1.	Clomiphene	37-46	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	90-94
28498812-5	2017	Moreover, knockdown of mutant IDH1 in HT1080 cells decreased the sensitivity to clomifene.	Clomiphene	80-89	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	30-34
28498812-7	2017	In short, our findings highlight clomifene may have clinical potential in tumor therapies as a safe and effective inhibitor of mutant IDH1.	Clomiphene	33-42	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	134-138
29134975-0	2017	Plasma Interleukin-1beta (IL-1beta) Concentrations at the Different Phases of the Oestrus Cycle in Clomiphene Treated Female Rats.	Clomiphene	99-109	interleukin 1 beta	Rattus norvegicus	7-24
29134975-0	2017	Plasma Interleukin-1beta (IL-1beta) Concentrations at the Different Phases of the Oestrus Cycle in Clomiphene Treated Female Rats.	Clomiphene	99-109	interleukin 1 beta	Rattus norvegicus	26-34
29134975-3	2017	It was thereforenecessary to determine plasma IL-1beta levels in female rats administered ovulation inducing agent clomiphene citrate.	Clomiphene	115-133	interleukin 1 beta	Rattus norvegicus	46-54
29134975-9	2017	The IL-1beta plasma concentrationswere higher in clomiphene treated rats at all the phases of the oestrus cycle of experimental rats when compared with thecontrol.	Clomiphene	49-59	interleukin 1 beta	Rattus norvegicus	4-12
29134975-10	2017	The increase in plasma IL-1beta was significant (p 0.05) in the estrus phase of the clomiphene citrate treated rats(550.53pg/ml) when compared with the control (304.42pg/ml).	Clomiphene	84-102	interleukin 1 beta	Rattus norvegicus	23-31
29134975-11	2017	The high plasma concentration of IL-1beta at the estrus phaseof clomiphene citrate treated rats suggests its possible involvement in oocyte maturation and ovulation which characterizesthe phase.	Clomiphene	64-82	interleukin 1 beta	Rattus norvegicus	33-41
29071945-0	2016	[Electroacupuncture Combined with Clomiphene Promotes Pregnancy and Blastocyst Implantation Possibly by Up-regulating Expression of Insulin Receptor and Insulin Receptor Substrate 1 Proteins in Endometrium in Rats with PCOS].	Clomiphene	34-44	insulin receptor	Rattus norvegicus	132-148
28137602-10	2017	Further characterisation of these newly identified hFMO3 substrates was performed determining their Km and kcat values that resulted to be 314 muM and 1.4 min-1 for selegiline and, 18 muM and 0.1 min-1 for clomiphene.	Clomiphene	206-216	CD59 molecule (CD59 blood group)	Homo sapiens	196-201
28090459-1	2016	OBJECTIVE: This study aimed to determine the threshold of anti-Mullerian hormone (AMH) as predictor of follicular growth failure in polycystic ovary syndrome (PCOS) patients treated with clomiphene citrate (CC).	Clomiphene	187-205	anti-Mullerian hormone	Homo sapiens	82-85
27228002-1	2017	Aim of the study was to asses and compare serum anti-Mullerian harmone (AMH) levels after laparoscopic ovarian drilling (LOD) and transvaginal hydrolaparoscopy (THL) ovarian drilling in clomifene citrate (CC)-resistant polycystic ovary syndrome (PCOS) patients; secondary outcome was to evaluate postoperative pain to estimate the acceptability of procedures.	Clomiphene	186-203	anti-Mullerian hormone	Homo sapiens	72-75
28042411-0	2017	Clomiphene Citrate Treatment Cycle Outcomes of Polycystic Ovary Syndrome Patients Based on Basal High Sensitive C-Reactive Protein Levels: A Cross-Sectional Study.	Clomiphene	0-18	C-reactive protein	Homo sapiens	112-130
29071945-0	2016	[Electroacupuncture Combined with Clomiphene Promotes Pregnancy and Blastocyst Implantation Possibly by Up-regulating Expression of Insulin Receptor and Insulin Receptor Substrate 1 Proteins in Endometrium in Rats with PCOS].	Clomiphene	34-44	insulin receptor substrate 1	Rattus norvegicus	153-181
25319474-0	2015	Effect of estradiol and clomiphene citrate on Erk activation in breast cancer cells.	Clomiphene	24-42	mitogen-activated protein kinase 1	Homo sapiens	46-49
27547681-9	2016	Intrauterine insemination can be done successfully at either 24 or 36 h after hCG in clomiphene citrate stimulated cycles.	Clomiphene	85-103	hypertrichosis 2 (generalised, congenital)	Homo sapiens	78-81
25897198-8	2015	Of the 17 women with FVL and/or PTG mutations, 7 (41%) experienced &gt;=1 miscarriage, 6 (35%) were on estrogen therapy, and 1 (6%) was on clomiphene.	Clomiphene	139-149	coagulation factor V	Homo sapiens	21-24
27475410-6	2016	Stimulation of spermatogenesis by gonadotrophins rFSH and/or hCG is the most used but others treatments, like pulsatile GnRH therapy or clomifene citrate can be used.	Clomiphene	136-153	hypertrichosis 2 (generalised, congenital)	Homo sapiens	61-64
27033325-0	2016	Clomiphene citrate down-regulates estrogen receptor-alpha through the ubiquitin-proteasome pathway in a human endometrial cancer cell line.	Clomiphene	0-18	estrogen receptor 1	Homo sapiens	34-57
27033325-1	2016	We examined how clomiphene citrate (CC) reduces estrogen receptor-alpha (ERalpha) in a human endometrial cancer cell line.	Clomiphene	16-34	estrogen receptor 1	Homo sapiens	48-71
27033325-1	2016	We examined how clomiphene citrate (CC) reduces estrogen receptor-alpha (ERalpha) in a human endometrial cancer cell line.	Clomiphene	16-34	estrogen receptor 1	Homo sapiens	73-80
26839488-0	2016	Genetic Polymorphism of CYP2D6 and Clomiphene Concentrations in Infertile Patients with Ovulatory Dysfunction Treated with Clomiphene Citrate.	Clomiphene	123-141	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-30
26839488-1	2016	CYP2D6 is primarily responsible for the metabolism of clomiphene citrate (CC).	Clomiphene	54-72	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
26559558-1	2016	The present retrospective cohort study was conducted to investigate whether serum anti-Mullerian hormone (AMH) levels, determined by either the Immunotech (IOT) or the second generation (Gen II) assay, can predict follicular recruitment in women with polycystic ovary syndrome (PCOS) undergoing ovulation induction with clomiphene citrate (CC).	Clomiphene	320-338	anti-Mullerian hormone	Homo sapiens	106-109
25319474-3	2015	In this study, we evaluate the effect of two fertilizing drugs, clomiphene citrate and estradiol, on the activation of Erk1/2 and the viability of two breast cancer cell lines, MCF-7 (hormone dependent) and BT20 (hormone independent).We show that both drugs induce Erk1/2 phosphorylation in MCF-7 and BT20 cells despite their opposite effect on cell viability.	Clomiphene	64-82	mitogen-activated protein kinase 3	Homo sapiens	119-125
25319474-3	2015	In this study, we evaluate the effect of two fertilizing drugs, clomiphene citrate and estradiol, on the activation of Erk1/2 and the viability of two breast cancer cell lines, MCF-7 (hormone dependent) and BT20 (hormone independent).We show that both drugs induce Erk1/2 phosphorylation in MCF-7 and BT20 cells despite their opposite effect on cell viability.	Clomiphene	64-82	mitogen-activated protein kinase 3	Homo sapiens	265-271
26692070-6	2015	In addition, pretreatment with estrogen receptor (ER) antagonists such as clomiphene, tamoxifen, or fulvestrant, significantly reversed the proliferative effect of each photoinitiator.	Clomiphene	74-84	estrogen receptor 1	Homo sapiens	31-48
25259724-0	2015	Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance.	Clomiphene	68-86	insulin	Homo sapiens	132-139
26692070-6	2015	In addition, pretreatment with estrogen receptor (ER) antagonists such as clomiphene, tamoxifen, or fulvestrant, significantly reversed the proliferative effect of each photoinitiator.	Clomiphene	74-84	estrogen receptor 1	Homo sapiens	50-52
24456700-0	2014	Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.	Clomiphene	10-28	gonadotropin releasing hormone 1	Homo sapiens	82-86
25815012-0	2015	Correlation of endometrial glycodelin expression and pregnancy outcome in cases with polycystic ovary syndrome treated with clomiphene citrate plus metformin: a controlled study.	Clomiphene	124-142	progestagen associated endometrial protein	Homo sapiens	27-37
25815012-2	2015	The purpose of this study was to evaluate the relationship between clomiphene citrate (CC) plus metformin treatment and endometrial glycodelin expression and to then correlate this relationship with pregnancy outcomes.	Clomiphene	67-85	progestagen associated endometrial protein	Homo sapiens	132-142
24592985-5	2014	There was a trend towards increasing cycle cancellation rates with GnRH antagonist/clomiphene citrate and GnRH antagonist/letrozole.	Clomiphene	83-101	gonadotropin releasing hormone 1	Homo sapiens	67-71
24419495-2	2014	SUMMARY ANSWER: Anti-Mullerian hormone (AMH) appeared to be an independent predictor of the required dosage of FSH to achieve monofollicular development for ovulation induction in a study sample of clomiphene-resistant PCOS patients.	Clomiphene	198-208	anti-Mullerian hormone	Homo sapiens	40-43
24456700-4	2014	The purpose of this prospective cohort study was to analyse the effect of clomiphene citrate on the endocrine profile in the luteal phase when using GnRH agonist trigger.	Clomiphene	74-92	gonadotropin releasing hormone 1	Homo sapiens	149-153
24456700-13	2014	The purpose of this prospective cohort study was to analyse the effect of clomiphene citrate on menstrual cycle day 2-6 on the hormone profile in the luteal phase when using GnRH agonist trigger.	Clomiphene	74-92	gonadotropin releasing hormone 1	Homo sapiens	174-178
22513911-15	2012	In studies comparing IVF versus IUI+SO, LBR per woman did not differ significantly between the groups among treatment-naive women (OR 1.09, 95% CI 0.74 to 1.59, 2 RCTs, 234 women) but was significantly higher in a large RCT of women pretreated with IUI + clomiphene citrate (OR 2.66, 95% CI 1.94 to 3.63, 1 RCT, 341 women).	Clomiphene	255-273	lamin B receptor	Homo sapiens	40-43
24482059-13	2014	This review includes two RCTs with low risk of bias that compared urinary human chorionic gonadotrophin (hCG) versus no treatment in anovulatory women receiving clomiphene citrate.	Clomiphene	161-179	hypertrichosis 2 (generalised, congenital)	Homo sapiens	105-108
24639797-11	2013	CONCLUSION: Chromium picolinate decreased FBS and insulin levels and, thus, increased insulin sensitivity in clomiphene citrate-resistance PCOS women.	Clomiphene	109-127	insulin	Homo sapiens	86-93
22916638-0	2012	[Insulin sensitivity in patients not responding to ovulation induction using clomiphene citrate].	Clomiphene	77-95	insulin	Homo sapiens	1-8
22916638-1	2012	BACKGROUND: The role of insulin resistance (IR) of infertile patients with chronic anovulation in their therapeutic failure to clomiphene citrate (CC) is not quite clear.	Clomiphene	127-145	insulin	Homo sapiens	24-31
22916638-2	2012	OBJECTIVE: Determine the sensitivity to insulin in patients with chronic anovulation and failure to the treatment with clomiphene citrate.	Clomiphene	119-137	insulin	Homo sapiens	40-47
22916638-11	2012	CONCLUSIONS: Our preliminary results suggest that insulin resistance can be a mechanism involved in the pharmacologic response to ovulation induction in infertile patients, but coexisting pathophysiological mechanisms such as hyperandrogenism might also account for the lack of response to clomiphene citrate.	Clomiphene	290-308	insulin	Homo sapiens	50-57
23979947-0	2013	The predictive value of circulating anti-Mullerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study.	Clomiphene	111-129	anti-Mullerian hormone	Homo sapiens	36-58
23604525-6	2013	Clomiphene, tamoxifen and toremifene were biotransformed to 22, 23 and 18 metabolites respectively, these phase I reactions being catalyzed mainly by CYP3A4 and CYP2D6 isoforms and, to a lesser degree, by CYP3A5, CYP2B6, CYP2C9, CYP2C19 isoforms.	Clomiphene	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-156
23604525-6	2013	Clomiphene, tamoxifen and toremifene were biotransformed to 22, 23 and 18 metabolites respectively, these phase I reactions being catalyzed mainly by CYP3A4 and CYP2D6 isoforms and, to a lesser degree, by CYP3A5, CYP2B6, CYP2C9, CYP2C19 isoforms.	Clomiphene	0-10	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	161-167
23604525-6	2013	Clomiphene, tamoxifen and toremifene were biotransformed to 22, 23 and 18 metabolites respectively, these phase I reactions being catalyzed mainly by CYP3A4 and CYP2D6 isoforms and, to a lesser degree, by CYP3A5, CYP2B6, CYP2C9, CYP2C19 isoforms.	Clomiphene	0-10	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	205-211
23604525-6	2013	Clomiphene, tamoxifen and toremifene were biotransformed to 22, 23 and 18 metabolites respectively, these phase I reactions being catalyzed mainly by CYP3A4 and CYP2D6 isoforms and, to a lesser degree, by CYP3A5, CYP2B6, CYP2C9, CYP2C19 isoforms.	Clomiphene	0-10	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	213-219
23604525-6	2013	Clomiphene, tamoxifen and toremifene were biotransformed to 22, 23 and 18 metabolites respectively, these phase I reactions being catalyzed mainly by CYP3A4 and CYP2D6 isoforms and, to a lesser degree, by CYP3A5, CYP2B6, CYP2C9, CYP2C19 isoforms.	Clomiphene	0-10	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	221-227
23604525-6	2013	Clomiphene, tamoxifen and toremifene were biotransformed to 22, 23 and 18 metabolites respectively, these phase I reactions being catalyzed mainly by CYP3A4 and CYP2D6 isoforms and, to a lesser degree, by CYP3A5, CYP2B6, CYP2C9, CYP2C19 isoforms.	Clomiphene	0-10	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	229-236
23250342-1	2013	PURPOSE: To compare the effectiveness and safety of controlled ovarian hyperstimulation (COH) using clomiphene citrate associated with gonadotropin and GnRH antagonist (CC + Ant) versus conventional COH without clomiphene citrate (Non-CC) for women undergoing assisted reproductive techniques (ART).	Clomiphene	100-118	gonadotropin releasing hormone 1	Homo sapiens	152-156
22815699-6	2012	Independent risk factors for SPTB-PPROM were shorter cervical length, short stature, participant"s not being the first born in the family, longer time to conceive, not waking up at night, hormonal fertility treatment (excluding clomiphene), mild hypertension, family history of recurrent gestational diabetes, and maternal family history of any miscarriage (risk reduction).	Clomiphene	228-238	spectrin beta, erythrocytic	Homo sapiens	29-33
22386763-0	2012	Influence of Val16Ala SOD2 polymorphism on the in-vitro effect of clomiphene citrate in oxidative metabolism.	Clomiphene	66-84	superoxide dismutase 2	Homo sapiens	22-26
22386763-8	2012	The results suggest that clomiphene citrate exhibits antioxidant activity similar to that observed with other selective oestrogen receptor modulators, and the intensity of the effect appears to be SOD2 polymorphism dependent.	Clomiphene	25-43	superoxide dismutase 2	Homo sapiens	197-201
22386763-12	2012	Significant differences of the clomiphene citrate antioxidant effect on PBMC with different Val16Ala SOD genotypes were observed in this study.	Clomiphene	31-49	superoxide dismutase 2	Homo sapiens	101-104
22386763-13	2012	Based on these results, we could speculate that alterations in SOD2 activity caused by the Val16Ala polymorphism can result in differential responses to drugs such as clomiphene citrate.	Clomiphene	167-185	superoxide dismutase 2	Homo sapiens	63-67
22108178-0	2012	Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.	Clomiphene	113-123	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	24-43
22108178-8	2012	A healthy female volunteer study confirmed our in vitro data that the CYP2D6 polymorphism substantially determines the formation of the active clomiphene metabolites.	Clomiphene	143-153	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	70-76
21807466-10	2011	Concerning PCOS, the correlation between AMH and LH can be used in the future for the assessment of the severity of PCOS, of the amelioration of PCOS under OCs treatment, as well as of the efficacy of infertility treatment in clomiphene resistant PCOS women.	Clomiphene	226-236	anti-Mullerian hormone	Homo sapiens	41-44
21831503-6	2011	Ovulation occurred in 120/187 cycles (64%) in the CC group and 95/184 cycles (51.6%) in the TMX group with a significant difference between two groups in favors of clomiphene (p=0.01).	Clomiphene	164-174	thioredoxin related transmembrane protein 1	Homo sapiens	92-95
21414307-8	2011	However, a pretreatment with clomiphene (an estrogen receptor antagonist) blocked the beneficial effects of ginsenoside Rb1 and estradiol, suggesting that the estrogen-like effects of ginsenoside Rb1 were estrogen receptor-dependent.	Clomiphene	29-39	RB transcriptional corepressor 1	Mus musculus	120-123
21693115-3	2011	Co-administration of clomiphene citrate along with human chorionic gonadotropin significantly increased hydrogen peroxide concentration and inhibited catalase activity in ovary, inhibited ovulation rate and induced egg apoptosis.	Clomiphene	21-39	catalase	Homo sapiens	150-158
21414307-8	2011	However, a pretreatment with clomiphene (an estrogen receptor antagonist) blocked the beneficial effects of ginsenoside Rb1 and estradiol, suggesting that the estrogen-like effects of ginsenoside Rb1 were estrogen receptor-dependent.	Clomiphene	29-39	RB transcriptional corepressor 1	Mus musculus	196-199